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CHAPTER I 
 
INTRODUCTION 
 
Atrial fibrillation is the most common sustained cardiac arrhythmia in adults with a 
rising incidence, and it is associated with significant increase in thromboembolic 
stroke risk and premature death.1 Identification of the first causative familial AF 
mutation (S140G) in the potassium channel gene KCNQ12 has shed some light 
on the molecular etiology of AF, and provides an avenue for exploring AF 
mechanisms and therapeutic opportunities. This chapter provides an overview of 
KCNQ1 biophysical properties, KCNQ1 function in cardiac physiology, gain-of-
function KCNQ1 mutations, and atrial fibrillation (AF). 
 
Biophysical properties of KCNQ1 
Voltage gated potassium (Kv) channels are transmembrane proteins that 
respond to alterations in membrane potential with conformational changes that 
allow potassium ions to move down their electrochemical gradient. The pore-
forming (α) subunit is the minimal functional unit of a Kv channel. Each six 
transmembrane domain α-subunit monomer has an intracellular N-terminus, four 
transmembrane segments (S1-S4) with S4 as the primary voltage-sensing 
domain, then a pore domain consisting of two transmembrane segments (S5 and 
S6) linked by the pore-loop, and a long intracellular C-terminus. Fully assembled 
channels are formed by homo- or heterotetramers of these α-subunits. α-
2 
 
subunits are grouped into 12 subfamilies (Kv1-12) each with unique 
characteristics.  
 
The Kv7 family channels are responsible for neuronal and muscular membrane 
excitability, and salt and water homeostasis. There are five members of this 
family, KCNQ1-5. KCNQ2-5 are primarily found in the central nervous system. 
KCNQ1, our focus, is expressed throughout the body in excitable and epithelial 
tissues, and is notably absent from the CNS. KCNQ1 is the only Kv7 member 
that assembles only into homo-tetrameters. Expressed alone, KCNQ1 produces 
a rapidly activating outward current with increasing current density in response to 
depolarizing voltage steps (Figure 1). When the membrane is repolarized to -30 
mV, KCNQ1 partially inactivates and its recovery forms a hook in the tail current 
reflecting recovery from the inactivated state before deactivation takes place. At -
80 mV, the channel fully deactivates.  
  
With functions in both excitable and non-excitable tissues, the KCNQ1 activity is 
diversified extensively through its interactions with auxiliary subunits and other 
factors. One class of auxiliary subunits is the single transmembrane domain 
KCNE family (1-5). The KCNEs are promiscuous, interacting with many Kv 
channels, and are differentially expressed in human tissue (Figure 2).3, 4 When 
expressed alone, the KCNEs do not generate any current. Yet when co-
expressed with KCNQ1, each KCNE differentially modulates the channel current 
(Figure 3). KCNE1 increases current amplitude, slows activation and  
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Figure 1. Biophysical properties of KCNQ1 current. Representative whole-cell currents 
elicited in CHO cells transiently transfected with KCNQ1 upon applying series of test 
potentials as illustrated in voltage-clamp protocols (membrane voltage indicated in mV). 
Modified from Ciampa, EJ, 2011.5 
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Figure 2. Relative expression of KCNQ1 and KCNE genes in human tissues. 
Several human tissues were examined by real-time quantitative RT-PCR. 
Tissues were grouped by low (A) and high (B) overall expression for display 
purposes (note differences in the y-axis scale). All data were quantified by gene 
specific standard curves and results were normalized by GAPDH expression. 
Data are presented as mean ± SEM for at least 6 replicates from 2 different 
pooled (2 or more individuals) cDNA samples isolated from healthy individuals. 
From Lundquist et al. 20064 
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Figure 3. Whole-cell currents recorded in CHO cells co-transfected with KCNQ1 and 
KCNE1-5. Each set of traces recorded using voltage-clamp protocol as indicated in box. 
Currents recorded upon +50 mV test depolarization illustrated in red for reference. 
Adapted from Ciampa, EJ 2011.5 
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deactivation rates, and positively shifts the voltage-dependence of activation. 
KCNE2 decreases current amplitude but results in constitutive channel activity. 
KCNE3 increases current amplitude and results in near-instantaneous channel 
activation. KCNE4 and KCNE5 dramatically inhibit channel activation. With 
KCNE5, supra-physiologic depolarization yields a slowly activating current. This 
diverse biophysical modulation contributes to the variable functions of KCNQ1. 
 
The slowly activating current produced by KCNQ1-KCNE1 channel complex, 
known as IKs, is further regulated by other factors in the cell (Figure 4). 
Adrenergic agonists stimulate cyclic AMP (cAMP) activation of protein kinase A 
(PKA), which phosphorylates Ser27 of KCNQ1.6 Critical to this phosphorylation 
event is the A-kinase anchor protein (AKAP) known as yotiao.6 With KCNE1 and 
yotiao co-expression, IKs current density is augmented in response to adrenergic 
stimulation. Another regulator of IKs is phosphaditylinositol-4,5-bisphosphate 
(PIP2).
7, 8 PIP2 is a minor acidic membrane lipid found primarily on the inner 
leaflet of the plasma membrane. PIP2 stabilizes the open state, increases current 
amplitude and slows deactivation of IKs. These examples emphasize the 
complexity of regulation of IKs within the cell.  
 
  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Topology and channel architecture of KCNE(purple) and KCNQ1 (blue) 
proteins. Topology of KCNE proteins as well as the delayed rectifier potassium channel 
KCNQ1 with indications of some of the domains important for regulation of the channel. 
Adapted from Jespersen et al, 2005.9 
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Figure 5. The relationship between ionic currents and the duration of the atrial action 
potential. The action potential is initiated by a rapid influx of Na+ ions (phase 0), followed 
by early (phases 1 and 2) and late (phase 3) stages of repolarization, before returning to 
the resting membrane potential (phase 4). Repolarization is controlled by a balance 
between inward (red) and outward (blue) currents. Adapted from Darbar and Roden, 
2013.10 
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KCNQ1 in cardiac physiology 
IKs is the slow component of the delayed rectifier potassium current in the heart. 
The heterologously expressed KCNQ1-KCNE1 complex recapitulates the key 
kinetics of the native cardiac IKs.
11, 12 This current is a critical component of 
cardiac repolarization within the action potential (Figure 5). The action potential 
generation is dependent on the finely tuned interaction between ion channels 
through the phases of rapid depolarization (phase 0), early repolarization (phase 
1), plateau phase (phase 2), late repolarization (Phase 3), and return to the 
resting membrane potential (phase 4). The action potential is initiated (phase 0) 
when a change in the membrane potential across the cell is sensed by sodium 
channel proteins, which alter their confirmation to open, allowing a large, rapid 
sodium influx. This current, INa, is mediated by ion channels composed of SCN5A 
(Nav1.5) and its ancillary subunits SCN1B (β1) and SCN2B (β2). During phases 
0, 1 & 2 L-type calcium channels are open, producing the depolarizing ICaL 
current. The interplay between calcium and the repolarizing potassium currents 
characterize the phases of repolarization. Early, rapid repolarization (phase 1) is 
due to outward movement of potassium ions from the transient outward current 
(ITO), composed of pore-forming Kv4.3 and β-subunit KChIP2. The plateau phase 
of the AP (phase 2) typically is a dome shape, representing the depolarizing 
effect of ICaL counteracting initial activation of the later repolarizing potassium 
currents (IKr, IKs, IKur). Late repolarization (phase 3) occurs as the balance shifts to 
the potassium currents and the calcium channels inactivate. The delayed 
rectifiers, with both a fast (IKr produced by HERG (Kv11.1)) and slow component 
10 
 
(IKs), are critical determinants of this phase. Final repolarization in this phase is 
accomplished by movement of potassium through inward rectifier channels 
KCNJ2 (Kir2.1), composing the IK1 current. IK1 also helps establish the resting 
membrane potential in Phase 4. Other ionic transporters (NCX, Na/K ATPase) 
help maintain ionic homeostasis during the large fluxes of the action potential. In 
addition to maintaining the repolarization of the normal cardiac action potential, 
the response of IKs to adrenergic stimulation is crucial. During stress or exercise, 
the sympathetic nervous system (α- and β-adrenergic stimulation) is activated. 
The augmentation of IKs from this stimulation aids in the shortening of the action 
potential with faster repolarization, required during heart rate acceleration. 
Importantly, the KCNE subunits are differentially expressed within the cardiac 
chambers suggesting a rather nuanced function of KCNQ1 within specific regions 
of the heart (Figure 6).  
 
Gain-of function KCNQ1 mutations in cardiac arrhythmias 
The importance of IKs is emphasized by the functional impact of mutations in 
these proteins or in relevant regulatory proteins that predispose to arrhythmias. 
Mutations in KCNQ1 causing dysfunction by defective trafficking, assembly, or 
regulation can lead to prolonged action potentials.13,14 During long action 
potentials, the calcium channels may be reactivated causing early after-
depolarizations. Delayed repolarization, as a consequence of KCNQ1 mutations, 
is reflected directly by a prolongation of the time interval between the initiation of   
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Relative expression of KCNQ1 and KCNE genes in human heart. Five 
human cardiac tissues were examined by real-time quantitative RT-PCR: right 
atrium (RA), left atrium (LA), right ventricle (RV), left ventricle (LV), and fetal 
heart (FH). All data were quantified by gene-specific standard curves and values 
were normalized to GAPDH expression. Data were presented as mean ± S.E.M. 
of at least six replicates from two different pooled cDNA samples derived from 
multiple individuals. From Lundquist et al. 2005.3 
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the QRS complex (ventricular depolarization) and the end of the T-wave 
(ventricular repolarization) recorded by a surface electrocardiogram (ECG). This 
prolonged QT interval caused by dysfunction in KCNQ1 characterizes one form 
of the long QT syndrome 1 (LQT1). A long QT interval can predispose to torsade-
de-pointes arrhythmia, ventricular fibrillation, and sudden cardiac death, 
particularly under conditions of adrenergic stimulation such as exercise or stress. 
Indeed, linkage analysis of LQT1 patients led to the identification of the KCNQ1 
gene and its original designation as KvLQT1 in 1996.13, 14 These loss of function 
mutations are the most common cause of inherited LQTS.  
 
While the KCNQ1 loss-of-function link to LQTS1 is well established, gain-of-
function KCNQ1 mutations have been more recently identified and are 
associated with increased AF susceptibility. The first identified gain-of-function 
KCNQ1 mutation was KCNQ1-S140G,2 and this mutation is the primary focus of 
this dissertation (Figure 7). The missense mutation was later identified as the 
causative mutation in a large Chinese family with autosomal-dominant early-
onset persistent AF (Figure 8).2 A neighboring mutation, V141M, was identified 
as a de novo KCNQ1 mutation responsible for AF.15 These two mutations are 
located near the extracellular end of the S1 transmembrane domain. When these 
mutant KCNQ1 subunits are expressed alone, the potassium currents are largely 
similar. However, when these mutant subunits are co-expressed with the KCNE1 
subunit, the outward currents generated were larger with more instantaneous  
13 
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Figure 8. Mapping analysis of the familial AF family with mutation KCNQ1-S140G. 
Diagonal lines through the symbols indicate deceased individuals. Each individuals ID 
number is listed below the pedigree symbol. Vertical bar represents chromosome 
segment. Selected markers spanning the 11p15.5 region are shown to the left of the 
pedigree, with each individual's allele shown next to the chromosome bar. The 
chromosome segment originating from the mutation carrying chromosome of the 
affected individual in the first generation (I-1) is represented by filled bars. Adapted from 
Chen, et al. 2003.2  
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current activation (Figure 9). Although these channels appear constitutively 
active, Restier et al elucidated that S140G-IKs and V141M-IKs actually had a 
markedly slowed rate of deactivation compared to WT-IKs.
17 With a long enough 
interval between pulses to allow for complete deactivation, the slowly activating 
gating kinetics of IKs could be restored to the mutant IKs. Nevertheless, even at 
slow physiologic heart rates these channels would be constitutively active.  
 
How these mutations confer constitutive activity in a KCNE1 obligate manner 
remains unclear. Restier et al hypothesize that these mutations may disrupt salt 
bridges that form in the open or closed state of the channel.17 In the open state 
model of the channel, S140 and V141 are in close proximity to E160 in S2 and 
R237 in S4 of the same subunit. Because E160 and R237 are predicted to form a 
salt bridge, disruption of this interaction could slow deactivation. An engineered 
mutation R237A, resulted in a channel with markedly slowed deactivation.18 
However, this slowed deactivation was not KCNE1 dependent. Alternatively, in 
the closed state E160 is predicted to interact with R231 while S140 and V141 
remain in close proximity (Figure 10).19 Either mutation might disrupt the E160-
R231 interaction resulting in slowed deactivation. Further, R231 and R237 are 
conserved charges in the S4 voltage sensor domain of KCNQ1.  
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Figure 9. KCNE1 modulates KCNQ1 and KCNQ1-S140G. Whole-cell patch clamp 
recording from COS-7 cells transfected with DNA encoding KCNQ1 (top row) or KCNQ1-
S140G (bottom row) alone (A) or with KCNE1 (B). Adapted from Bendahou, et al. 
2005.16 
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Figure 10. Structural model of KCNQ1 in the closed state from the "extracellular" side 
looking into the pore. Left: Full view; The backbone of each individual Q1 α-subunit is 
shown as a different colored ribbon. The space filled atoms for the S140 (pink), E160 
(purple), and R231 (orange) residues are shown in each α-subunit. Right: Red α subunit 
magnified. The side chains of S140 and E160 are predicted to be close enough to form 
van der Waals contacts with R231 in the closed state. Adapted from Bartos et al 2011.19  
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Supporting the disruption of this interaction as a broader AF mechanism are the 
recently described familial AF (FAF) associated mutations R231H and 
R231C.19,20 R231H was identified in 5 unrelated families causing high penetrance 
for early onset AF.20 Electrophysiological studies demonstrate an increase in IKs 
is predicted to shorten the action potential duration in atrial cells. Similarly, 
R231C has been linked to FAF.19 While R231C-IKs was constitutively active, 
overall there was not an increase in current density as seen with S140G-IKs or 
V141M-IKS. This constitutive activity was still predicted with computational 
modeling to shorten the atrial action potential. Complicating the association of 
these KCNQ1 mutations with FAF is the noted pleiotropy with QT prolongation. 
While not highlighted in the original publication, many family members with 
S140G mutation also demonstrated a prolonged QT interval. In addition, the 
R231 site was associated first with LQTS. Although R231C has constitutive 
activity, the overall decrease in current density also classifies it as a loss-of-
function mutation. Indeed, R231C is linked to LQT1 in other families. R231H-IKs 
did not increase with PKA activation consistent with the borderline and 
adrenergic-induced QT prolongation seen in some patients. Nevertheless these 
mutations together suggest a FAF 'hotspot' dependent on KCNE1.  
 
  
19 
 
Although these identified FAF mutations possibly have a similar mechanism, an 
unrelated KCNQ1 mutation and mutations in auxiliary subunits or interacting 
partners that augment potassium current also are associated with early onset 
FAF. KCNQ1-IAP54-56 is a duplication and insertion of the amino acids IAP in 
the N-terminus of KCNQ1.21 This FAF mutation resulted in larger and faster 
activation, but not constitutively activity, of IKs. A mutation S64R in natriutetic 
peptide precursor A (NPPA) increased the current density and activation rate of 
IKs as well.
21 Although we have focused on IKs, mutations in other KCNEs have 
also been linked to FAF and increased KCNQ1 current density: KCNE2-R27C,22 
KCNE2-X124N,23 KCNE3-V17M.24 The identification of these mutations suggest 
a general increase in KCNQ1 current can result in increased AF susceptibility. 
 
These in vitro data are consistent with the theory that increased K+ current from 
these mutation would cause shortening of atrial action potentials in myocytes. 
Nevertheless, these studies are limited by the mutation characterization in a 
heterologous expression system, which does not completely recapitulate the 
native myocyte condition. Moreover, predicted effects on action potentials were 
demonstrated through computational modeling, which again may not completely 
recapitulate the native myocytes. One attempt to evaluate an FAF mutation in a 
native myocyte was the use of a mouse model with myocardial specific (α-
cardiac MHC promoter) transgenic overexpression of KCNQ1-S140G.25 While 
the mutation caused frequent episodes of atrioventricular block that could be 
terminated by the KCNQ1-specific inhibitor HMR-1556, episodes of AF were not 
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observed.25 These data suggest that mouse cardiac myocytes are not an 
appropriate cellular model of the human phenotype in this genetic disorder. Also 
missing from this discussion is the fact that familial AF does not present during 
childhood suggesting that genetic predisposition alone is not sufficient to cause 
the disease. A brief discussion of AF provides a framework for how FAF 
mutations relate to disease manifestation and provide possible therapeutic 
opportunities. 
 
Atrial fibrillation  
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults. 
The prevalence for AF increases exponentially with age, affecting <1% under 50 
years old, 6% over 65 years old, and 11% over 75 years old.26 Because of our 
aging population, AF’s incidence in the US is projected, by one estimate, to 
increase from 2.3 million in 2000 to nearly 16 million in 2050.26 AF is 
characterized by a rapid, irregular electrical activation of the atria that leads to 
quivering or fibrillation of the chamber musculature resulting in impaired 
propulsive force. Short periods of AF result in palpitations, light-headedness, and 
shortness of breath. Long durations of AF can lead to heart failure, and 
thromboembolic complications such as stroke, due to stasis of blood within the 
atria. AF confers a 6x increased risk for ischemic stroke and is associated with 
premature death.27 The cost of AF is estimated to exceed $6 billion annually.28 
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The majority of AF, known as secondary AF, occurs within the context of 
structural heart disease, such as congestive heart failure or coronary artery 
disease, with onset past the age of 65. An estimated 10-30% of AF, designated 
as lone AF or LAF, does not occur in the context of overt heart disease and has 
an age of onset less than 65 years.29-32 Genetic predisposition to AF has been 
demonstrated in populations33, 34 and in families segregating specific mutations.35 
These mutations include potassium channels2, 15, 22, 24, 36-40 and sodium 
channels.41-43 LAF that runs in families is also termed familial AF. While identified 
FAF mutations shed light on the underlying basis of FAF susceptibility, the 
molecular etiology of AF is still not well understood. Current theories about the 
pathogenesis of AF involve triggers acting on a susceptible substrate that 
induces AF. In a substrate with increased IKs, the action potential duration (APD) 
is predicted to be shortened. One manner in which AF would be more likely to 
develop in this circumstance is that the tissue effective refractory period (ERP) 
would be abbreviated. If triggered, this abbreviated ERP could give rise to the 
development of reentrant circuits. Because FAF does not present during 
childhood, other factors acquired during life are presumed to interact with the 
genetically determined cellular substrate for the full clinical presentation (Figure 
11). The additive or synergistic effects of combined genetic and acquired factors 
in determining AF susceptibility has not been explored at the mechanistic level.  
The anticipated contribution of these factors to substrate susceptibility varies 
depending on type of AF and age of onset (Figure 12).  
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Figure 11. A 'two-hit' hypothesis states that a combination of genetic (blue) and an 
acquired (green) risk factor is required for the development of atrial fibrillation. Darbar 
and Roden, 2013.10  
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Although interactions between genetic and acquired factors can lead to AF 
substrate susceptibility and AF development, the currently available therapeutics 
are not mechanistically targeted and coarsely applied to all AF arrhythmias 
regardless of genesis. While AF can be categorized by presumed etiology, for 
therapeutic purposes AF is categorized into three types based on episode 
duration: paroxysmal (lasts less than 7 days, terminates spontaneously), 
persistent (does not terminate spontaneously but can be converted to sinus 
rhythm), or permanent. Repeated episodes of AF lead to electrical remodeling of 
the atria and progression of AF to an increasingly persistent or permanent state. 
To treat the AF arrhythmia itself, the basic strategies fall to either rate or rhythm 
control. A number of clinical trials have explored whether pharmacological rate or 
rhythm control confer different outcomes and have found no difference in patient 
survival between rate and rhythm control strategies.44-46 Current guidelines from 
the American College of Cardiology (ACC), American Heart Association (AHA), 
and European Society of Cardiology (ESC) recommend a rate control strategy for 
all asymptomatic patients.47 For rate control, the primary categories of  
therapeutics are β-blockers such as atenolol or propranolol, calcium channel 
blockers such as verapamil, and digoxin. Rate control alone can often diminish 
AF symptoms. However, many patients find AF symptoms intolerable and rhythm 
control is pursued. Pharmacologically sinus rhythm can be with restored sodium 
channel blockers such as flecainide or propafenone, or multi-channel blockers 
such as amiodarone or quinidine. Many of these blockers are broad and block a 
number of specific ion channels. Further these ion channel blockers can put 
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patients at risk of ventricular arrhythmias such as QT prolongation and torsade 
de pointes, hypotension, and other side effects. Because long-term use of 
antiarrhythmics is often undesirable or not efficacious, rhythm control sometimes 
can be achieved through electrical cardioversion or radiofrequency ablation of 
the AV node, the AF circuit, or ectopic foci near the pulmonary veins. Despite 
expansion in our understanding of the genetic basis of AF, genotype or 
mechanism focused therapies for AF are lacking and there remains an 
opportunity for personalized genotype-directed therapy. 
 
Objective 
As summarized above, KCNQ1 is a widely expressed pore forming voltage gated 
potassium subunit. Together with the auxiliary subunit KCNE1, KCNQ1 forms the 
slow component of the delayed rectifier potassium current, IKs. In the heart, IKs is 
critical for the repolarization and for action potential shortening in response to β 
adrenergic stimulation. Loss-of-function mutations in IKs lead to LQT1 while gain-
of-function mutations have been linked to familial AF susceptibility. A group of 
FAF associated mutations, S140G, V141M, R231H, and R231C, have 
constitutive activity in part because of impaired deactivation. These residues are 
hypothesized to interact in the closed state model of the channel suggesting a 
common mechanism. Nevertheless, how these observed properties in 
heterologous systems translate to a native myocyte is not known. Furthermore, 
because AF does not present in childhood, what acquired factors are needed for 
clinical manifestation of the disease is unknown.  
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In our approach, we focused on KCNQ1-S140G, the first identified and best 
studied causative mutation associated with familial AF. Because transgenic 
mouse models of KCNQ1-S140G did not produce AF, we first focused on 
developing a native rabbit atrial myocyte model system as a model organism to 
better elucidate the mechanism of AF associated with KCNQ1-S140G. In this 
dissertation, we test the hypotheses that KCNQ1-S140G causes increased atrial 
potassium current density with resulting shortening of action potential duration by 
investigating the cellular consequences of KCNQ1-S140G in rabbit atrial 
myocytes. Lastly, we explored targeted genotype-specific therapy of this 
mutation based on the hypothesis that KCNQ1-S140G has distinct 
pharmacological properties that render it susceptible to targeted inhibition.  
 
  
27 
 
CHAPTER II 
 
HIGH YIELD MULTI-CHAMBER ISOLATION, CULTURE, AND 
TRANSFECTION OF ADULT CARDIOMYOCYTES  
 
Introduction 
While the electrophysiological effects of many FAF mutations have been 
described in heterologous sytems, how these mutations alter an adult atrial 
action potential is not known and only hypothesized through the use of 
mathematical modeling. FAF-linked mutations expressed in transgenic mice 
illustrate how different the mouse atria is than human atria and some cases 
rather inadequate for evaluating the AF phenotype.25 The difficulty in isolating 
robust yields adult atrial myocytes is a key methodological issue for connecting 
the observed heterologous electrophysiological defects with the increased AF 
susceptibility observed in families.  
 
Rabbits are a well-studied model and are commonly used for whole-heart and 
tissue studies. Rabbit cardiomyocytes are more human-like than cardiomyocytes 
isolated from mouse, rat or guinea pig due to expression of important potassium 
currents such as the slow delayed rectifier current, IKs (not expressed in mouse 
or rat myocytes), and the transient outward current, Ito (not present in guinea pig 
myocytes). In addition, rabbits are significantly more economical and useable in a 
laboratory with standard equipment than larger animals such as pig, dog or 
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sheep. Acutely isolated primary cells are more physiologically native than 
immortalized cardiac cell lines. Another alternative cell platform, human iPSC-
derived cardiomyocytes, offers immature myocytes that exhibit 
electrophysiological properties more similar to neonatal than adult cells.48  
 
We developed methods for high yield isolation of adult atrial myocytes 
concomitantly with ventricular myocytes from both guinea pig for preliminary 
methods development and rabbits for experiments. We describe novel 
modifications to the classic Langendorff enzymatic isolation method to produce 
reliable yields of adult rabbit atrial myocytes. We developed cultured conditions 
to extend the viability of these myocytes, and identified adenovirus as a reliable 
transfection method for exogenous protein expression in these cells. Further, we 
demonstrate the utility of cultured adult atrial myocytes for electrophysiological 
experiments.  
 
Methods 
 
Cardiac myocyte isolation from adult guinea pigs 
Myocytes were isolated from adult Hartley guinea pigs 250-300g of either sex 
(Charles River USA), as previously described with modifications.49  
 
  
29 
 
Preparation 
Three solutions were prepared for isolation: physiologic saline solution (PSS) 
with and without Ca2+ (Table 1) and Kraft-Brühe solution (KB) (Table 2). For a 
single isolation, solutions were divided into tubes as indicated in Table 3. All 
solutions were bubbled with 100% O2 for duration of use, except digestion 
solution for which bubbling was stopped after enzyme was added to avoid 
frothing. Before each isolation, the peristaltic pump was adjusted to 5 ml per min 
flow rate with water filled tubing (1.42 mm internal diameter). Due to tubing 
stretch over the course of each isolation, the rate needed to be increased with 
each subsequent isolation. The tubing was changed approximately every 10 
isolations when the top pump speed was unable to achieve required flow rate. 
The water bath temperatures were adjusted so the solution was 35°C at the 
cannula. 
 
Anesthesia and surgery 
The guinea pig was weighed and then anticoagulated with 500 units heparin 
injected intraperitoneally (i.p.) in the lower abdominal quadrant using a 25 gauge 
needle. After 5 mins, the guinea pig was anesthetized with 100 mg/kg of 
pentobarbital (i.p.) When the guinea pig no longer responded to a firm ear pinch, 
it was placed on the dissecting area, ventral side up, and limbs were secured 
with tape. The chest was shaved and wiped down with 70% ethanol. Withdrawal 
reflexes, tested with a firm toe pinch, were monitored frequently. Areflexia onset 
typically occurred 5 min after pentobarbital administration.   
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Table 1. Physiologic saline solution components 
 mM 
NaCl 140 
KCl 5.4 
MgCl2 2.5 
Glucose 11 
HEPES 5.5 
± CaCl2 1.5 
pH 7.4 at 37°C 
Table 2. Kraft-Brühe solution components 
 mM 
K-glutamate 110  
KH2PO4 10 
KCl 25 
MgSO4 2 
Taurine 20 
Creatine 5 
EGTA 0.5 
Glucose 20 
HEPES 5 
pH 7.4 at 37°C 
Table 3. Solution division for guinea myocyte isolation 
Solution ml Use 
dH2O 40 Rinsing bubbler between solutions 
PSS + Ca2+ 50 Dissecting dish 
PSS + Ca2+ 30 1st 5 min perfusion 
PSS 30 2nd 5 min perfusion 
PSS 50 20 min digestion 
KB 50 Trituration, filtering and plating 
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Heart excision 
After a deep plane of anesthesia was achieved, a small incision was made below 
the xiphoid process and the ribcage was cut away from the diaphragm. Using 
large scissors, the ribcage was removed by cutting along either side. The great 
vessels were secured with curved tweezers. Scissors cut above the tweezers to 
remove the heart and ensure enough residual aorta length for cannulation. 
 
Aortic cannulation 
The heart was immediately placed in a dissecting dish with warmed PSS + Ca2+ 
solution. The heart was gently massaged between fingers to expel excess blood 
from the ventricles. Extra tissue, such as the lung and aortic arch, were removed.  
The aorta was cannulated on a 1/16" female Luer lock connector with 200 series 
barb and secured with surgical thread.  
 
Perfusion and enzymatic digestion 
The heart was mounted on a Langendorff perfusion apparatus and perfusion was 
begun with PSS + Ca2+ for 5 min. The coronary vessels were monitored for blood 
clearance, and the aorta was re-cannulated if necessary to achieve full perfusion. 
Then perfusate was switched to PSS and the heart was monitored for lack of 
contraction as calcium stores were depleted. After 5 mins, perfusate was 
switched to PSS with 0.4 mg/ml collagenase II (Worthington, Lot #49H11299). 
The enzymatic perfusion was continued for 18 min if the guinea pig was <300 g 
or 20 min for larger animals. Perfusate was recycled as needed. 
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Tissue dispersion 
After digestion termination, the heart was placed in a 60 mm dish with KB 
solution. The desired portions of the heart (any chamber) were separated and 
placed in a new dish. The tissue was coarsely minced with scissors, and gently 
triturated with a wide-tipped plastic transfer pipette. The supernatant was filtered 
through 100 μM nylon mesh into either an Eppendorf tube (atria) or 15 ml conical 
tube (ventricle).  
 
Washes and plating 
The myocytes were centrifuged slowly to form a loose pellet (500 rpm, 3 min). 
The supernatant was removed and the cells resuspended in fresh KB solution. 
This wash step was repeated. For acute experiments, myocytes were stored at 
4°C in KB solution. For culture experiments, myocytes were plated in tissue 
culture dishes, incubated at 37°C, and after 3 h, solution was changed to warmed 
culture media.  
 
The experimental procedure for isolating guinea pig cardiac myocytes was 
approved by Vanderbilt University Institutional Animal Care and Use Committee.  
 
Cardiac myocyte isolation from adult rabbits 
 Myocytes were isolated from hearts of male New Zealand White rabbits (6-7 lbs 
from Charles River Canada), using the method of Bassani, et al.50 with significant 
modifications. 
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Preparation 
Prior to isolation, initial wash, enzyme wash, and bovine serum albumin (BSA) 
solutions (Table 4) were prepared from a 1L of 10x MEM solution (Table 5). 
Solutions were filtered into sterile containers and stored at 4°C . On the day of 
isolation, each solution was heated to 37°C and the pH was brought to 7.35. For 
each isolation, 400 ml initial wash, 200 ml enzyme solution, and 400 ml BSA 
solution were prepared. The peristaltic pump flow and recycling lines were 
checked for integrity. The flow rate was calibrated to 25 ml/min. Because the 
elasticity of the pump tubing decreased with each use, pump speed was 
increased as needed to ensure the proper flow rate. Pump tubing typically can be 
used for 10 isolations. The temperature at the cannula was confirmed to be 37°C. 
After the heart was mounted, the temperature of the solution exiting the heart at 
this flow rate was 35°C. The initial wash and enzyme solutions were bubbled with 
95% O2 - 5% CO2 gas. Note that the concentration of sodium bicarbonate used 
was specific for this gas composition. When bubbling with 100% oxygen, 4.76 
mM NaHCO3 was used.  
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Table 4. Rabbit isolation solutions components 
Initial wash solution Enzyme wash solution BSA solution 
NaHCO3 23.8 mM NaHCO3 23.8 mM NaHCO3 23.8 mM 
  Taurine 8 mM BSA 1% 
  CaCl2 0.02 mM CaCl2 0.5 mM 
 
Table 5. 10x Rabbit isolation MEM solution 
MEM powder 
(Joklik modification without NaHCO3) 
119 g 
Insulin 400 units 
Penicillin-Streptomycin 50,000 units 
Pyruvic acid 24.9 mM 
Na-HEPES 100 mM 
HEPES 100 mM 
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Sedation and anesthesia 
After transfer from the animal facility to lab, rabbits were kept in a covered carrier 
with ambient nature sounds playing to reduce anxiety for at least 20 min. If the 
rabbit was agitated in the animal facility, the time was increased to 1 h. Rabbits 
that vocalized or thumped in the animal facility were not transferred, and the 
isolation was delayed for at least one day. After anxiety subsided, rabbits were 
sedated with 2.4 mg/kg acepromazine, injected intramuscularly in the caudal 
thigh muscle. The rabbit was returned to the carrier with eyes covered by gauze 
to further reduce anxiety. After 5-15 min, the rabbit typically was non-responsive 
to a strong ear pinch. The rabbit was placed on the dissection platform, and the 
ear was cleaned with 70% ethanol. Using a thumb to occlude and distend the 
dorsal ear vein, the vein was cannulated with a 23 gauge butterfly infusion 
needle and intravenous 40 mg/kg pentobarbital sodium and 1000 units heparin 
were administered. The anesthesia level was monitored frequently by checking 
corneal and withdrawal reflexes and assessing heart rate. If arreflexia was not 
achieved in 20 min, additional i.v. bolus of 20 mg/kg pentobarbital sodium was 
administered. The dissection plane was prepared by spraying with 70% ethanol, 
shaving fur and applying betadine soap to the skin. 
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Heart excision 
After achieving a deep plane of anesthesia, a midline incision was made and the 
fascial plane was cut to expose the chest muscle. The abdominal wall was 
incised below the xiphoid process. The xiphoid process was grasped with 
tweezers and poultry shears were used to cut along the sternum for a 
thoracotomy. The chest cavity was opened with retractors and the rapidly 
contracting heart was visualized. The pericardium was torn and removed. The 
great vessels were secured between fingers and cut with fine scissors as distally 
from the heart as possible to ensure that enough ascending aorta was preserved 
for Langendorff cannulation. The heart was lifted vertically and remaining 
pulmonary vessels were cut to release the heart. 
 
Langendorff perfusion 
After rapid excision of the heart, it was arrested on ice. Over the course of 5 min, 
the heart was transferred between three cold beakers of initial wash solution and 
the heart was inverted between washes to flush blood from the ventricles. At the 
end of 5 min, the aorta was grasped with tweezers and cannulated on a barbed 
Luer coupler. Initially the aorta was secured with an alligator clip and then more 
securely tied with surgical thread. Then through the aorta, the coronary vessels 
were flushed with 30 ml of cold initial wash solution applied by a syringe. If blood 
was not cleared from the coronary vessels (Figure 13), the cannula was 
repositioned more distal to the heart because the coronaries occasionally branch 
from proximal ascending aorta.  
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Figure 13. Representative example of coronary vessels clearing in an adult rabbit heart. 
A, Adult rabbit heart with coronary vasculature filled with blood after excision from rabbit. 
B, Same adult rabbit heart with cleared coronary vasculature after retrograde aortic 
perfusion with 30 ml initial wash (see methods).  
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The heart was then mounted on a Langendorf perfusion apparatus and perfusion 
was begun at 37°C for 10-15 min with initial wash solution gassed with 95% O2 
and 5% CO2. As the heart warmed to 37°C, it typically began contracting for a 
few minutes. Because the initial wash solution was nominally calcium free, the 
heart should stop contracting once the calcium stores are depleted.  
 
Atrial perfusion 
During this initial perfusion and once the heart stopped contracting, the 
pulmonary vessels were closed with microvessel clips to perfuse both atrial 
chambers at high pressure (Figure 14). The atrial chambers were punctured 
twice at their apex with a 22 gauge needle. These punctures should not deflate 
the atria but rather facilitate flow of solution. 
 
Initial enzymatic digestion 
After sufficient atrial perfusion rate was achieved, Liberase TH (Roche Applied 
Sciences, Indianapolis, IN) was thawed and added to the enzyme wash solution 
at 0.05 mg/ml. Due to its hydroscopic properties, Liberase TH upon arrival was 
suspended in sterile H2O and stored in 1 ml aliquots (5 mg/ml) at -20°C. The 
enzyme was used within 3 months. The perfusion solution was carefully switched 
to avoid perfusion of air bubbles in the enzyme wash solution. After 1 min, the 
recycling line was switched to the enzyme wash solution. After 5 min, a small 
incision was made in the left ventricle in an area between major coronary vessels  
(Figure 15). 
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Figure 14. Atrial perfusion on the Langendorff apparatus. A, microvessel clamps 
occlude pulmonary veins to perfuse the atria. B, high pressure perfusion inflates the left 
atrial chamber. 
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Figure 15. Representative sampling site for enzymatic digestion monitoring. A, Whole 
heart orientation to sampling location and B, enlarged view of sampling site on left 
ventricle between major coronary vasculature.  
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Serial tissue samples (30 s - 1 min) were taken from this incision with fine 
tweezers and inspected immediately by light microscopy. When the majority of 
ventricular myocytes released were quiescent rods (7-20 min) (Figure 16), the 
atria were removed from the heart and placed in enzyme solution. The remaining 
heart was placed in BSA solution on ice. 
 
Atrial enzymatic digestion 
Either atrium was recannulated on the Langendorff apparatus (Figure 17). Serial 
samples were taken from the perfused atrium until the sample edges contained 
packets of rod-shaped atrial myocytes and the majority of released atrial 
myocytes were quiescent rods (5-20 minutes) (Figure 18). Typically, atria 
digestion was not complete until the tissue lost integrity and samples were 
difficult to grasp with tweezers. The atrium was removed and placed in BSA 
solution. The other atrium was recannulated on the apparatus and the digestion 
process repeated.   
 
Tissue dispersion 
The desired tissue was finely minced, gently triturated with a wide-bore pipette, 
and the supernatant filtered through a 100 μm cell strainer (BD Biosciences, San 
Jose, CA). These steps were repeated until all tissue had been filtered. The 
myocytes were allowed to settle into a soft pellet by gravity for 30 – 60 min at 
room temperature. Then the supernatant was aspirated, and myocytes were 
resuspended in fresh BSA solution.   
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Figure 16. Serial sampling of rabbit adult left ventricular myocyte during enzymatic 
digestion. A through D show serially collected samples examples. A, early sample with 
few mostly hypercontracted cells; B, majority of myocytes released are hypercontracted; 
C, mix of hypercontracted and rod-shaped ventricular myocytes; D, majority of cells 
released are rod-shaped, an ideal time to stop ventricular enzymatic digestion.  
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Figure 17 Representative examples of secondary atrial cannulation on Langendorff 
apparatus; A, Left atrial cannulation and B, right atrial cannulation.  
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Figure 18. Serial sampling of rabbit adult left atrial myocytes during enzymatic 
digestion. Rows represent sampling progression. Left column is the margin of sample 
and right column illustrates released myocytes morphology. A and B, early sample with 
few rod shaped myocytes visible at sample margin and few released myocytes. C and 
D, intermediate sample with mix of rod-shaped and hypercontracted myocytes both at 
sample margin and released. E and F, ideal sample for digestion termination with rod-
shaped myocytes in loose packets at tissue margin and majority of released myocytes 
are rod-shaped.  
45 
 
The experimental procedure for isolating rabbit cardiac myocytes was approved 
by Vanderbilt University Institutional Animal Care and Use Committee.  
 
Staining of acutely isolated cardiac myocytes 
Rabbit cardiac myocytes membranes and t-tubules were stained as previously 
described.51 Briefly, acutely isolated cells from all four cardiac chambers were 
stained with wheat germ agglutinin conjugated to Alexa-flour 594 and fixed with 
4% paraformaldehyde. Importantly, membranes were not permeabilized prior to 
staining. Samples were stored in PBS suspension at 4°C. 
 
Culture of adult cardiac myocytes 
 
Myocyte culture media 
Three myocyte culture media bases were used for guinea pig myocyte culture 
optimization: MEM with Hank's salt (Table 6), Media 199 (Table 7), and Ham's F-
10 (Table 8). Excitation-contraction couplers used were 2,3 butane-dione 
monoximine (BDM) at 10-30 mM and blebbistatin (BLB) 5-200 μM. pH buffer 
augmentation was achieved with addition of 4 mM NaHCO3 and 10 mM HEPES 
and pH to 7.4 at 37°C with NaOH. Media was added 15 min - 5 h post isolation.  
  
46 
 
 
 
Table 6. MEM-based myocyte culture media components 
MEM with Hank's salt 500 ml  
Penicillin 50 units/ml 
Streptomycin 50 μg/ml 
BSA 1% 
Insulin-transferrin-selenium-X 1x 
 
Table 7. Media 199-based myocyte culture media components 
Media 199 500 ml  
Penicillin 50 units/ml 
Streptomycin 50 μg/ml 
L-carnitine 2 mM 
Creatine 5 mM 
Taurine 5 mM 
 
Table 8. Ham's F-10-based myocyte culture media components 
Ham's F-10 250 ml 
DMEM 250 ml 
Penicillin 50 units/ml 
Streptomycin 50 μg/ml 
Insulin 1 mg/ml 
Transferrin 5 mg/ml 
LiCl/NaSeO4 0.01 mM 
Thyroxine 0.1 mM 
Ascorbic acid 2.5 mM 
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For adult rabbit myocytes, cells were placed into culture 3 h post isolation with 
media consisting of MEM supplemented with Hank’s salts, 2 mM L-glutamine 
(Gibco-Invitrogen, Life Technologies, Grand Island, NY), insulin-transferrin-
selenium-X supplement, penicillin (50 units/ml), streptomycin (50 μg/ml), 1% 
bovine serum albumin, 10 µM blebbistatin at pH 7.4 at 37°C (modified from 
Kabaeva, et al. 2008 52). 
 
Coating cover slips with extracellular matrices 
Laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane 
(Sigma-Aldrich St. Louis, MO), fibronectin (Roche Applied Sciences, 
Indianapolis, IN), or poly-L-lysine (VWR, Radnor, PA) were used to coat glass 
coverslips to promote myocyte adherence. Laminin was diluted 1mg to 50 ml 
MEM solution and stored in 1 ml aliquots at -20°C. Laminin was used at 100 μl to 
each 15 mm round cover slip. Fibronectin was prepared by adding 1 ml water to 
1 mg fibronectin and incubating for 10 mins at 37°C with 5% CO2. Then 20 ml 
MEM plus 1% penicillin/streptomycin was added. Fibronectin was stored at -
20°C. Fibronectin was used with 100 μl per 15mm round cover slip. 0.01% poly-
L-lysine solution (Trevigen, Gaithersburg, MD) was stored at 4°C. 1 ml was used 
to coat a 35 mm dish. After addition of any matrix, the dish was incubated at 
37°C with 5% CO2 for at least 1 h. The excess matrix was removed. Culture 
media was added for storage or the dish was used immediately for myocyte 
culture. 
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Transfection of adult cardiac myocytes 
Human KCNQ1 and KCNE1 cDNAs were generated as described previously.3 
The S140G mutation was engineered in KCNQ1 using QuikChange mutagenesis 
(Stratagene Corp, La Jolla, CA). For most test transfections, empty vector 
controls were used, either pIRES2-eGFP or pIRES2-dsRedMST. All constructs 
were verified by sequencing of the entire open reading frames. 
 
Electroporation 
Acutely isolated guinea pig myocytes were electroporated using the ECM 830 
(BTX, Harvard Apparatus, Inc., Holliston, MA) with pIRES2-eGFP plasmids using 
permutations of the following parameters: time post isolation (5 min - 3 h), 
temperature (4°C , 20-23°C, or 37°C), suspension media (PBS, KB, DMEM, 
culture media), DNA amount (1-20 μg), field strength (250-1000V), and pulse 
duration (3-7 ms). Poly(ethylenimine) (PEI) (Sigma-Aldrich St. Louis, MO) was 
also used to enhance transfection, but was found to be immediately toxic to 
myocytes even at low concentration when combined electroporation.  
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Lipid transfection 
Transient lipid transfection of adult cardiac myocytes was attempted with 
pIRES2-eGFP plasmid in multiple ratios with different lipid transfection reagents: 
FuGENE6 (Promega, Madison, WI), FuGENEHD (Promega, Madison, WI), 
SuperFect (Qiagen Inc, Valencia, CA), Lipofectamine 2000 (Invitrogen, Life 
Technologies, Grand Island, NY), Lipofectamine LTX (Invitrogen, Life 
Technologies, Grand Island, NY), and Lipofectamine Plus (Invitrogen, Life 
Technologies, Grand Island, NY). PEI was added to promote transfection. For 
lipofectamine trials, conditions were tested with and without a 3 h incubation at 
1% CO2. 
 
Biolistic transfection 
 
Preparation of DNA bullets 
Gold beads (12.5, 25, or 50 mg of 0.6, 1.0, or 1.6 micron) were added to an 
Eppendorf tube. Then, 100 μl of 0.05M Spermidine was added. The tube was 
sonicated for 20 s., 12.5-100 μg DNA diluted in dH2O for 50 μl total volume was 
then added, and sonicated. While vortexing the eppendorf (at level 5), 100 μl of 
1M CaCl2 was added dropwise to the tube. The tube was briefly sonicated. The 
solution was allowed to precipated at room temperature for 10 min. The tube was 
briefly centrifuged, the supernatanted aspirated, and resuspended in 3.2 ml fresh 
100% ethanol or 100% ethanol- polyvinylpyrollidone (PVP) mixture (0.007, 0.015, 
or 1.0 mg/ml ethanol). Well-shaken mixture was loaded into bullet tubing, 
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previously dried for at least 20 min with 0.4 lpm N2, and fed into the prep station. 
After 4 min, the supernatant was carefully removed. The tubing was slowly 
turned to evenly distribute gold, and then spun continuously for 20 sec on the 
prep station. The tubing was dried for 5 min with N2 gas. The tubing was cut into 
0.5" shells with a tube cutter. The bullets were stored in scintillation vials with 
DriRite and stored at 4°C. Bullets were used within 3 months of preparation. 
 
Biolistic transfection of myocytes 
The bullet vial was allowed to reach room temperature and loaded into the Helios 
Gene Gun (Bio-Rad Laboratories, Hercules, CA) cartridge holder. The gun was 
assembled and attached to helium tank. The media was aspirated from target 
cell culture dishes. The gun was aimed parallel to tissue culture dish, either point 
black or using the barrel length as a spacer. The gun was fired at 50-350 PSI. 
Fresh culture media was immediately added to cells. An example set-up is 
illustrated (Figure 19). 
 
 
  
51 
 
 
 
 
 
Figure 19.  Biolistics method for transfection of adult cardiac myocytes. A, schematic of 
the protocol employed for transfection of freshly isolated adult rat ventricular myocytes 
using the Helios Gene Gun; B, top: wide field fluorescence and bright field overlay image 
of adult rat ventricular myocytes transfected with eGFP acquired with a 10x objective. 
The transfected myocyte glows green. Middle: a rate vetnricular myocyte transfected 
with mCherry acquired with 60x objective. Bottom: an untransfected myocyte imaged as 
for mCherry. Adapted from Dou, et al. 2010.53 
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Lentiviral transduction 
 
Lentiviral plasmids 
Lentivirus was generated using plasmids (pLL-eGFP, PAX2, and pMD2.G) that 
were a generous gift of Nick Markham in Al Reynold's laboratory at Vanderbilt 
University. A payload plasmid was created from pLL-eGFP to express pLL-CMV-
mcs-IRES2-dsRedMST.  
 
Lentivirus generation 
Lentivirus was generated using the following protocol. On day 0, HEK 293FT 
cells were plated at 1x106 in 60 mm dishes to acheive 50-70% confluency the 
following day. On day 1, a calcium phosphate transfection was prepared. First 12 
μl of 25 mM chloroquine (stored at -20C) was added to 293FT cells. Then 
transfection cocktail was prepared in the following order: 6.6 μg of payload 
plasmid (pLenti-CMV-mcs-IRES2-dsRedMST), 5 μg of packaging plasmid 
(PAX2), 2 μg envelope plasmid (pMD2.G), 21 μl 2M CaCl2, up to 170 μl sterile 
dH2O and 170 μl BES-1 buffer (500 ml stock): 5.33 g BES powder (Calbiochem), 
8.18 g NaCl, 0.75 ml of 1.5 mM Na2PO4 and pH 6.95 with NaOH. The cocktail 
was mixed for 15s with a P1000 pipette. The mixture was added to 293FT cells 
dropwise and slowly swirled to mix. Cells were incubated 5-7 h and then fresh  
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media was added. On day 2, the culture media was changed. On day 3, the virus 
was harvested with a 10 ml syringe and passed through a 0.45 micron filter. The 
harvested virus was stored at 4°C for up to a week or stored at -80°C for up to a 
year in small single use aliquots.  
 
Lentiviral transduction 
For transduction, a small amount of media was added to plated myocytes. 
Polybrene (8 μg/ml) was added to the media. Virus was added to the cells and 
incubated for 3-12 h. Then, the media was replaced. Cells were monitored daily 
for fluorescent expression of viral marker (dsRedMST). 
 
Adenoviral transduction 
 
Adenoviral vectors 
Adenoviral vectors, pAd5-CMVK-NpA and pAd5-(9.2-100)delta1.6KbE3, were 
obtained from the University of Iowa Gene Transfer Vector Core (supported in 
part by the NIH and the Roy J. Carver Foundation). Using the pAd5-CMVK-NpA 
vector, we created a shuttle vector for IRES2-dsRedMST.  
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Adenovirus generation 
Adenovirus was generated using the RAPAdTM system as previously described 
(Figure 20).54 In brief, each shuttle vector and the backbone vector pAd5-(9.2-
100)delta1.6KbE3 were co-precipitated with calcium-phosphate into human 
embryonic kidney (HEK) 293 cells in 60 mm Petri dishes. When 60% of cells had 
detached (12-14 days), the cells and media were harvested, lysed through 
repeated freezing/thawing cycles, and amplified in HEK cells (typically using 5-10 
150 mm Petri dishes). After 60% of cells detached from the large dishes (1-3 
days), cells were pelleted by centrifugation and resuspended 5 ml of viral storage 
solution (10 mM Tris, 2 mM MgCl2, 4% sucrose, pH 8.0). The supernatant was 
stored at −80°C and the virus was used within 3 months for test transductions. 
Myocytes were incubated with virus for 24 h, and transduction rate was 
evaluated at 48 h. 
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Figure 20. Adenovirus generation vectors. Shuttle vector was created by cloning 
dsRedMST vector into adenoviral multi-cloning site. Both shuttle and backbone vector 
were digested with Pac1 restriction enzyme to linearize. Linear shuttle and backbone 
vectors were transfected with calcium-phosphate into HEK293 cells where they 
underwent homologous recombination to create full adenoviral vector. Intracellular 
replication and amplification in cells yielded adenovirus capable of transducing the 
dsRedMST gene into target cells. Adapted from University of Iowa Gene Transfer Core. 
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Voltage clamp electrophysiology 
Potassium currents were recorded from myocytes cells using the whole-cell 
configuration of the patch clamp technique.55 The extracellular solution contained 
in mM: 137 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2, 10 Glucose, 10 HEPES, 0.05 CdCl2, 
pH 7.4. The standard intracellular solution contained in mM: 110 K Glutamate, 10 
KCl, 10 NaCl, 14 EGTA, 5 HEPES, 2 CaCl2, 5 Mg-ATP, pH 7.2. Pipette solution 
was diluted 5-10% to prevent activation of swelling-activated currents. Patch 
pipettes were pulled from thick wall borosilicate glass (World Precision 
Instruments, Inc.) with a multistage P-97 Flaming-Brown micropipette puller 
(Sutter Instrument Co., Novato, CA) and heat-polished with a Micro Forge MF 
830 (Narashige International USA, Inc., East Meadow, NY). After heat polishing, 
the resistance of the patch pipettes was 2-4 megaohms in the standard solutions. 
A 2% agar bridge with composition similar to the control bath solution was used 
as a reference electrode. Unless otherwise stated, all chemicals were obtained 
from Sigma-Aldrich (St. Louis, MO). 
 
Whole-cell currents were recorded at room temperature (20–23°C) using an 
Axopatch 200B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Test 
pulses were generated using Clampex 8.1 (MDS Analytical Technologies), and 
whole-cell currents were acquired at 5 kHz and filtered at 1 kHz. The access 
resistance and apparent membrane capacitance were estimated as described 
previously.56 Whole-cell currents were not leak subtracted. Junction potentials 
57 
 
were zeroed with the filled pipette in the bath solution. All recordings were started 
4 min after achieving a whole cell patch.  
 
For guinea pig atrial myocyte potassium currents, whole-cell currents were 
measured during a series of 2 s voltage steps from a holding potential of −40 mV 
to test potentials ranging from −40 to +60 mV (in 10 mV increments) followed by 
a 1 s step to −30 mV to record tail currents with a 10 s interpulse duration. Due to 
presence of an endogenous inward background potassium current in guinea pig 
atrial myocytes,57 the cells needed to be held at a higher holding potential than -
80 mV to prevent activation of this current. 
 
For rabbit atrial myocyte potassium currents, whole-cell currents were measured 
during a series of 2 s voltage steps from a holding potential of −80 mV to test 
potentials ranging from −80 to +60 mV (in 10 mV increments) followed by a 1 s 
step to −30 mV to record tail currents with a 20 s interpulse duration. The 
extended interpulse duration was used to allow for recovery of the transient 
outward potassium current, Ito.  
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Current clamp electrophysiology 
Action potentials were elicited from atrial myocytes using the whole-cell 
configuration of the patch clamp technique55 and previously described 
solutions.58 The extracellular solution contained in mM: 140 NaCl, 5.4 KCl, 1 
MgCl2, 1 CaCl2, 7.5 glucose, 0.33 NaH2PO4, and 5 HEPES, pH 7.4. The 
intracellular solution contained in mM: 120 KCl, 10.25 NaCl, 5 MgCl2, 0.36 CaCl2, 
5 HEPES, 5 EGTA, 5 creatine phosphate (Tris), 5 glucose, and 5 K2ATP, pH 7.2. 
Patch pipettes were pulled from thick wall borosilicate glass (World Precision 
Instruments, Inc., Sarasota, FL) with a multistage P-97 Flaming-Brown 
micropipette puller (Sutter Instrument Co., Novato, CA) and heat-polished with a 
Micro Forge MF 830 (Narashige International USA, Inc., East Meadow, NY). 
After heat polishing, the resistance of the patch pipettes was 1.5-2.5 megaohms 
in the above solutions. A 2% agar bridge with composition similar to the control 
bath solution was used as a reference electrode.  
 
Action potentials were elicited at room temperature (20–23°C) using an Axopatch 
700B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Pulses were 
generated using Clampex 9.1 (MDS Analytical Technologies), and action 
potentials were acquired at 10 kHz. No current was injected to maintain resting 
membrane potentials. To elicit action potentials, a stimulus threshold was 
determined for each myocyte, using a protocol of 0.1 nA steps of 3-4 ms duration 
(Figure 21).  
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Figure 21. Eliciting action potentials from adult cardiac myocytes. A, Example of 
threshold protocol with square wave current injection to determine optimal stimulus to 
elicit action potential with overstimulus exceeding the action potential amplitude (top 
trace), smooth activation of the action potential (middle trace), and understimulus with 
delayed activation of the AP, the threshold of AP activation (lowest AP). B, Example of 
AP elicited at optimal stimulus with no activation artifact, typically 1.25x threshold 
stimulus; C, Example of action potential before and after small leak (<50 mV) leak 
developed in the seal; D, Example of action potential as whole-cell seal closes, 
increasing the mV during the stimulus pulse. 
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Results 
 
Calcium-tolerant cardiac myocytes 
High yields of calcium-tolerant cardiac myocytes from all chambers were 
obtained for both adult guinea pig and adult rabbit hearts. Once the optimal lot of 
collagenase II was identified and digestion time was determined empirically, 
guinea pig ventricular and atrial myocytes could be isolated simultaneously. The 
key step for high yield of guinea pig atrial myocyte isolation was waiting 3 h 
before adding culture media or bath solution for patch clamp experiments when 
cells get exposed to physiologic levels of calcium. Slow calcium titration or 
shorter recovery period resulted in hypercontraction of myocytes. Ventricular 
myocytes could tolerate exposure to higher calcium concentrations earlier than 
atrial myocytes. Acutely isolated myocytes had crisp cellular borders and clearly 
visible striations (Figure 22).  
 
While guinea pig atrial and ventricular myocytes could be isolated simultaneously 
with high yields, rabbit atrial myocyte isolation proved more challenging. 
Modifications to the traditional Langendorff method were critical to achieve high 
yields of rabbit atrial myocytes. First, the pulmonary vessels were clamped with 
microvessel clips to inflate both atrial chambers at high pressure in order to 
achieve atrial perfusion. The atria were then punctured at their apex to facilitate 
the drainage of the perfusate without loss of pressure. Further, we found  
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Figure 22. Acutely isolated guinea pig adult cardiac myocytes. A, left atrial myocytes 
and B, left ventricular myocyte captured at 40x with light microscopy.  
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enzymatic digestion using Liberase TH was more reliable with less lot-to-lot 
variability than commonly used collagenases. To monitor the progression of the 
enzymatic digestion, we employed a novel serial sampling technique that 
enabled a reproducible high yield of isolated cardiomyocytes. For ventricular 
digestion, a small superficial incision was made in the ventricular wall within the 
area between the major coronary vessels. Serial tissue samples were excised 
every 0.5-1.0 minutes from the incised myocardium and the extent of myocyte 
release was assessed immediately by light microscopy. When the majority of 
released myocytes appeared as quiescent (non-contracting) and rod-shaped, the 
left and right atria were removed from the heart and placed in enzyme solution 
while the remaining cardiac chambers (right and left ventricles) were placed in 
cold BSA-solution to stop enzymatic activity. 
 
Critical to rabbit atrial myocyte isolation and exclusive to our protocol, each 
atrium was recannulated one at a time on the Langendorff apparatus (modified 
Langendorff prep) and enzymatic perfusion was resumed. Serial tissue samples 
were taken from the atrial wall and examined by light microscopy until the 
majority of cells released were quiescent and rod-shaped. Then, the atrium was 
removed from the perfusion apparatus. The desired segments of atrial and 
ventricular tissue were minced in BSA solution, gently triturated, and filtered. 
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Three key steps further enriched the percentage of rod-shaped myocytes by 
separating them from hypercontracted, dying cells and preventing cellular 
damage. First, the healthy myocytes were allowed to settle into a loose pellet by 
gravity for 30 minutes at room temperature, leaving unhealthy myocytes in 
suspension. Second, after myocyte resuspension in fresh BSA solution, the cells 
were plated on laminin-coated coverslips. Healthy myocytes express laminin 
receptors and adhere to laminin within 1 h. Non-adherent dying myocytes lacking 
intact laminin receptors get removed with subsequent washes. Third, myocytes 
anchored to laminin were then left to recover for 2-3 h after the completion of 
enzymatic digestion before being exposed to physiologic calcium levels in either 
bath solution for electrophysiology experiments or media for extended culture. 
Healthy myocytes had crisp borders with clearly visible striations (Figure 23). The 
time elapsed between the enzymatic digestion and the exposure to high calcium 
concentration solutions permits the healing of the cell membranes. Again, atrial 
myocytes were found to be more sensitive than ventricular myocytes. Ventricular 
myocytes could better tolerate centrifugation or early calcium exposure than atrial 
myocytes. Both yields improved with the gentler methods of  gravity filtration and 
longer recovery times before calcium exposure. 
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Figure 23. Acutely isolated rabbit adult cardiac myocytes. A, left atrial myocyte and B, 
left ventricular myocyte, captured at 63x with light microscopy.  
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Optimizing culture conditions for adult cardiac myocytes 
Because we wanted to express mutant potassium channels in adult cardiac 
myocytes and most transfection methods typically need 48 h for protein 
maturation, we sought to optimize culture conditions to extend myocyte viability. 
Most published experiments with adult cardiac myocytes have been conducted 
acutely.  
 
First, because cardiac myocytes do not adhere to glass coverslips and lack of 
adherence results in significant decrease in viability and differentiation,59 we 
explored three extracellular matrices for cell culture plating: laminin, fibronectin, 
and poly-L-lysine. Cardiac myocytes adhered to all three matrices. However, 
poly-L-lysine allowed the adherence of all cells, regardless of cell viability. With 
fibronectin and laminin, dead or dying myocytes, known to express fewer of the 
required receptors, did not adhere and were aspirated with the subsequent 
exchange of culture media. There was no significant difference in myocyte 
viability or morphology noted between cardiac myocytes plated on laminin or 
fibronectin. Laminin is significantly less expensive, so all experiments were 
conducted with this more economical option.  
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During our initial myocyte isolations from guinea pig heart, we tested three 
different bases for myocyte culture media: MEM + Hank's salt, Media 199, Ham's 
F-10. Initial cultures showed highest number of striated myocytes after 48 h in 
MEM + Hank's salt base (Figure 24). However, after 72 h, a significant number of 
myocytes had blebs and difficult to see striations. Based on the insights in 
Kabaeva et al (2008)52 on culture of adult mouse cardiac myocytes, we explored 
two critical facets to optimize our myocyte cell culture: addition of buffer and 
excitation-contraction (EC) uncoupler.  
 
Although MEM + Hank's salt media contains buffer chemicals to maintain pH, the 
addition of sodium bicarbonate and HEPES plus bringing the pH to 7.4 at 35°C 
significantly improved the health of myocytes based on cell morphology (Figure 
25). Further, the myocyte media retained pH sensitive phenol red color after 24 h 
incubation with the added buffer compared to the yellow color indicating <7.0 pH 
in the non-augmented media. 
 
Because isolated adult cardiac myocytes tended to dedifferentiate in culture, the 
addition of EC uncouplers in culture have been employed to help maintain cell 
morphology and cell differentiation. For example, 2,3 butane-dione monoximine 
(BDM), developed in 1955 initially as a chemical phosphatase,60, 61 is a well-
characterized non-competitive inhibitor of skeletal muscle myosin-II.62 However, 
milimolar concentrations of BDM are required to uncouple EC in myocytes.  
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Figure 24. Representative guinea pig adult atrial myocytes cultured with different media 
bases for 48 h. A, MEM-base cultured myocyte with crisp membrane borders, some 
visible striations and minor membrane blebs evident; B, F-10 base cultured myocyte with 
significant blebs and rounded ends, C, Media 199 base media with no visible striations, 
some blebs, and indistinct membrane borders. 
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Figure 25. Buffer augmentation in media increases myocyte health in culture. 
Representative 48 h cultured adult guinea pig myocytes with and without buffer 
augmentation. A, B, guinea pig left atrial myocytes and C, D guinea pig left ventricular 
myocytes cultured without pH buffer augmentation in left column (A, C) and with pH 
buffer augmentation in right column (B,D). Buffer augmentation significantly decreases 
membrane bleb formation and membrane striations are more distinct. 
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At these concentrations, BDM has been shown to inhibit voltaged-gated calcium 
currents,63 transient outward potassium currents,64 sodium-calcium exchanger65 
and gap junction communication.66 We explored using a different EC uncoupler, 
blebbistatin (BLB). Identified in 2003, BLB binds to the ADP-Pi complex of 
myosin II with high affinity in the micromolar range,67 and was first used as an EC 
uncoupler in cardiac myocytes in 2008.52 BLB is now commonly used in rabbit 
whole-heart optical mapping to limit movement artifacts.68 BLB has also been 
shown not to inhibit critical ionic currents in myocytes at these concentrations.69 
We tested both BDM and BLB as EC uncouplers in guinea pig myocyte culture. 
Cardiac myocytes treated with BLB had increased viability, membrane integrity, 
and maintained morphology of adult cardiac myocytes (Figure 26). 
 
However, high concentrations of BLB made myocyte membranes stiff and difficult 
to achieve a seal in whole cell patch clamp experiments. We tested 
concentrations of 1-200 μM BLB to achieve optimal balance in maintaining cell 
viability and achieving whole cell patch clamp. Lower concentrations slightly 
decreased the yield of viability myocytes over time and cell membrane edges 
were less crisp but did facilitate the ability to achieve whole cell patches for 
electrophysiology experiments. We used 5 μM as the minimal concentration of 
BLB concentration required to maintain myocyte viability and differentiation. All 
rabbit myocytes were cultured using this concentration of BLB with optimized 
media and added buffer on laminin (Figure 27).   
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Blebbistatin extends culture viability of guinea pig adult myocytes. A, B,C are 
representative adult guinea pig left atrial myocytes and D,E,F are representative adult 
guinea pig left ventricular myocytes after 120 h in cultured with either no EC uncoupler 
(left column, A,D), 30 mM BDM (middle column B, E), or 100 μM BLB (right column 
C,F).  
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Figure 27. Representative adult rabbit myocytes cultured for 72 h in optimized culture 
conditions; A, left atrial myocyte and B, left ventricular myocyte.  
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Transfection of adult cardiac myocytes 
Having established optimal culture conditions for adult cardiac myocytes, we 
used several methods to attempt to transfect these myocytes with plasmids 
expressing dRedMST: electroporation, lipid transfection, biolistics, lentivirus and 
adenovirus. Extensive experiments and many permutations of variables were 
unsuccessful in transfecting with electroporation or lipid based methodology. 
Variable success was achieved with biolistics, lentivirus and adenovirus. 
 
Biological ballistics, or biolistics using the "gene gun", is a method that has 
recently been successfully employed to transfect acutely isolated adult rat 
ventricular myocytes.53 In biolistics, DNA is precipitated on to small gold beads 
with calcium phosphate. These 'bullets' are loaded into small tubes or 
'cartridges,' which are then shot with an air gun, specifically designed 'gene gun,' 
using helium gas at adjustable pressure. We optimized this method for 
transfection of adult guinea pig atrial myocytes. We observed the highest 
transfection rates using larger gold beads (1.6 μm diameter), 100 PSI, a PVP 
concentration of 0.015 mg/ml, 0.5 mg of gold delivered per shot (microcarrier 
loading ratio), 2 μg DNA to 1 mg gold (for a 2:1 DNA loading ratio), and shooting 
from a distance equal to the barrel length. Further, highest myocyte survival was 
achieved if cells were shot 24 h post-isolation. Expression of dsRedMST could 
be visualized 24 h after transfection, 48 h after isolation (Figure 28).  
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Figure 28. Biolistic transfection of adult guinea pig atrial myocytes with dsRedMST. A, 
bright field image at 10x with bullets visible B, same field under fluorescence illustrating 
expression of dsRedMST in myocytes. 
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Unfortunately, biolistics did not succeed with the more fragile adult rabbit atrial 
myocytes. In particular, the pressure used to shoot the atrial myocytes could not 
be refined to transfect the atrial myocytes without killing the cells whereas lower 
pressures resulted in the bullets 'rolling' off the atrial myocytes. 
 
Two different viral delivery systems, lentivirus and adenovirus, were employed to 
optimally transduce rabbit atrial myocytes. Lentivirus transduction of guinea pig 
myocytes was successful. Lentivirus had the advantage of fast virus generation 
time (3-5 d), but the resulting titers are inconsistent. In addition, the time to 
transgene expression was over 5 days and the transduction rate had a very low 
efficiency. Lentivirus integrates into the target cell genome, which could have 
deleterious effects. This property is more optimal for creating stable cell lines. 
Due to these limitations, we opted for the longer to generate (6 weeks) but more 
reliable transduction with adenovirus. Using dsRedMST expression maker, both 
adult guinea pig and rabbit atrial myocytes were transduced with adenovirus at 
high efficiency in a shorter time frame (2 days) (Figure 29) .  
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FIgure 29. Adenoviral transduction of guinea pig and rabbit adult atrial cardiac myocytes 
with dsRed-MST. A, 10x fluorescent image of guinea pig atrial myocytes expressing 
dsRedMST and B, 40x bright-field (R) and fluorescent image (L) of a single guinea pig 
atrial myocyte. C, 10x fluorescent image of rabbit atrial myocytes expressing 
dsRedMST; D, 40x bright-field (R) and fluorescent image (L) of a single rabbit atrial 
myocyte. 
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Electrophysiology of adult cardiac myocytes 
To ascertain whether cardiac myocytes cultured under the conditions we 
developed maintained hallmark electrophysiological properties, we conducted 
whole-cell patch clamp experiments to ascertain potassium currents (Figure 30). 
Previously described differences were observed between guinea pig and rabbit 
atrial cardiac myocytes. Guinea pig atrial myocytes had a distinct background 
inward potassium current. To best measure outward potassium current, we held 
the resting membrane potential at -40 mV. Slowly activating outward currents 
consistent with predominantly IKs and IKr were observed. In rabbit atrial myocytes, 
a significant fast activating current was noted and attributed to Ito. Because of 
significant run-down of Ito with short interpulse duration (5s), the interpulse 
duration was extended to 20s to better record the outward current properties. 
Further, action potentials elicited from cultured guinea pig and atrial myocytes 
were consistent with anticipated results (Figure 31).  
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Figure 30. Representative potassium current recording from cultured adult atrial cardiac 
myocytes. Potassium currents from 48 h cultured A, guinea pig left atrial cardiac 
myocyte and B, rabbit left atrial cardiac myocyte/ 
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Figure 31. Representative action potential recording from cultured adult atrial cardiac 
myocytes. Action potentials from 72 h cultured A, guinea pig left atrial cardiac myocyte 
action potential and B, rabbit left atrial cardiac myocyte action potential. 
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Discussion 
We developed methods for high yield isolation, extended culture, and 
transfection of adult cardiac myocytes suitable for electrophysiological 
experiments. While guinea pig atrial and ventricular myocytes could be isolated 
simultaneous once an optimal lot of collagenese II was identified and digestion 
time was empirical determined, multi-chamber isolation of adult rabbit myocytes 
required more extensive modifications to the traditional Langendorf methods. 
Using a novel serial sampling technique, we were able to achieve reproducible 
high yields of both ventricular and atrial myocytes. Importantly, the optimal 
digestion time varied widely between rabbit heart preparations. After achieving 
optimal ventricular digestion, left and right atria are removed and sequentially 
recannulated for further perfusion (modified Langendorff preparation). Yields of 
calcium tolerant cardiomyocytes were further enriched by gravity pelleting rather 
than centrifugation between wash steps, plating on laminin-coated coverslips, 
and at least a 2 h recovery time before exposure to physiological levels of 
calcium in culture media.  
 
The culture of adult cardiac myocytes with preserved morphology for 5 days was 
optimized though the use of laminin as an extracellular matrix to promote cell 
adherence, the identification of MEM as a base for culture media, the 
augmentation of pH buffering capacity, and the use of a low concentration of the 
E/C-uncoupler, blebbistatin. Although the transfection of adult cardiac myocytes 
was not achieved through multiple parameter optimization of electroporation and 
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lipid-based methods, biolistics and viral methods were successful. Using 
biolistics, guinea pig atrial myocytes were reliabley transfected with rapid 
fluorescent marker gene expression time (<24 h); whereas rabbit atrial myocytes 
proved too fragile to withstand biolistic impalement. Lentiviral and adenoviral 
methods both were successful to transduce adult cardiac myocytes; adenovirus-
mediated transduction was most efficient with high titers and robust expression of 
in myocytes. Electrophysiology confirmed the utility of these isolated cultured 
myocytes for future experiments.  
  
The key advantage to these methods is the ability to isolate robust quantities of 
high quality adult mammalian cardiomyocytes from both atria and ventricles at 
the same time and from the same animal with a reliable method to monitor 
enzymatic digestion progression for both chambers to determine their best 
termination time. The availability of large quantities of healthy isolated adult atrial 
myocytes adds considerable value to studying adult arrhythmias such as atrial 
fibrillation, the most common sustained cardiac arrhythmia encountered in the 
clinical practice. 
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There are limitations to using isolated cardiomyocytes from any source. Because 
these are isolated primary cells, studies are limited to answering specific 
questions related to single cells such as the duration of the action potential and 
the characteristics of component ionic currents. Determining the effective 
refractory period, measuring conduction velocity, and analyzing the development 
of arrhythmogenic foci are better answered at the tissue or whole heart level.  
 
Isolated atrial and ventricular adult guinea pig and rabbit myocytes can be used 
for the acute study of their structural (microanatomy), functional and 
pharmacological properties (electrophysiology and calcium dynamics). Robust 
yields of high quality cells are fundamental to obtain reproducible results and 
expand the opportunities to subacute studies such as viral transduction for gene 
overexpression or suppression with RNA interference that require short term 
tissue culture. Cultured myocytes also provide a platform for longer term studies 
of drug toxicity. Using these developed methods, we explore the effects of 
familial atrial fibrillation mutation, KCNQ1-S140G, expression on adult rabbit cardiac 
myocytes.  
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CHAPTER III 
 
FAMILIAL ATRIAL FIBRILLATION ASSOCIATED KCNQ1 MUTATION  
SHORTENS ADULT RABBIT ATRIAL ACTION POTENTIAL DURATION AND 
INCREASES TRIGGERED ACTIVITY 
 
Introduction 
Atrial fibrillation is the most common sustained cardiac arrhythmia and its 
incidence is exponentially increasing in our society with an anticipated affected 
population exceeding 16 million by 2050.1 Recent identification of monogenic 
causes of atrial fibrillation have provided insight into the substrate susceptibility 
required for the generation of the AF phenotype. Intriguingly, although the 
electrophysiological consequences of these mutant FAF-associated genes are 
present at birth, the clinical manifestation of FAF does not occur until later in life 
suggested the necessity of acquired factors for the full clinical phenotype. 
Electrophysiological characterization of KCNQ1 mutations associated with FAF 
suggest a gain-of-function phenotype with many mutations resulting in 
constitutive activity in physiologic conditions.2, 15, 19, 20 Mathematical modeling has 
been used to extrapolate the results of these gain-of-function mutation to atrial 
myocytes, but no studies have investigated the consequences of expression in 
native atrial myocytes.  
  
83 
 
Having established cell isolation conditions and exogenous gene expression 
methods for rabbit atrial myocytes in the previous chapter, our approach here is 
to investigate the consequences of S140G-IKs expression in rabbit atrial 
myocytes. We hypothesized that expression would shortened action potential 
duration. At a tissue level, this abbreviated APD would contribute to a shortened 
tissue effective refractory period, leaving the atria vulnerable to triggered re-
entrant circuits. We tested this hypothesis by first electrophysiologically 
characterizing the endogenous expression of IKs in rabbit atrial myocytes and 
then by using a modified adenovirus to exogenously express S140G-IKs in adult 
rabbit atrial myocytes.  
 
Here we present evidence that under our recording conditions IKs is not 
endogenously expressed in rabbit atrial myocytes. Further, to express IKs in 
rabbit atrial myocytes, a modified adenoviral promoter must be used to generate 
the potassium channel expressing virus and that a very high MOI is necessary to 
generate expression. In S140G-IKs expressing myocytes, we demonstrated 
evidence of triggered activity at low frequency stimulation and a shorter action 
potential duration at higher frequency with hyperpolarized resting membrane 
potential compared to WT-IKs expressing myocytes. Overall, we illustrate effects 
of the FAF-associated mutation S140G-IKs in a native adult atrial myocyte 
supporting the notion that a shortened APD likely underlies substrate 
susceptibility. 
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Methods 
 
Adenoviral vectors 
Human KCNQ1 and KCNE1 cDNAs were generated as described previously.3 
The S140G was engineered in KCNQ1 using QuikChange mutagenesis 
(Stratagene Corp, La Jolla, CA). Adenovirus vectors, pAd5-CMVK-NpA and 
pAd5-(9.2-100)delta1.6KbE3, were obtained from the University of Iowa Gene 
Transfer Vector Core (supported in part by the NIH and the Roy J. Carver 
Foundation). Using the pAd5-CMVK-NpA vector, we created shuttle vectors for 
KCNQ1-IRES2-DsRedMST, S140G-IRES2-DsRedMST, KCNE1-IRES2-eGFP, 
and IRES2-DsRedMST. Shuttle vectors were initially made using the CMV 
promoter. However, using this promoter, the KCNQ1 and S140G shuttle vectors 
failed to generate a virus. Thus a modified CMV promoter was used for all shuttle 
vectors. This modified promoter consisted of the CMV immediate early promoter 
sequence immediately followed by the last 358 nucleotides of IRES2. This 
modification was hypothesized to attenuate promoter efficiency and enabled 
more efficient generation of KCNQ1 encoding adenovirus.  
 
Adenoviral generation 
Adenovirus was generated using the RAPAdTM system as previously described.54 
In brief, each shuttle vector and the backbone vector pAd5-(9.2-
100)delta1.6KbE3 were co-precipitated with calcium-chloride into human 
embryonic kidney (HEK) 293 cells in 60 mm Petri dishes. When 60% of cells had 
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detached (12-14 days for KCNE1 and vector-only viruses; 17-25 days for KCNQ1 
and S140G), the cells and media were harvested, lysed through repeated 
freezing/thawing cycles, and amplified in HEK cells (typically using 5-10 150 mm 
Petri dishes). After 60% of cells detached from the large dishes (1-3 days), cells 
were pelleted by centrifugation and resuspended in 5 ml of viral storage solution 
(10 mM Tris, 2 mM MgCl2, 4% sucrose, pH 8.0). Cells were then lysed and 
centrifuged. The supernatant was stored at −80°C in single use aliquots and the 
virus was used within 5 months. 
 
Adenoviral confirmation 
Activity of each virus prep was confirmed for fluorescent marker (Figure 32) and 
potassium channel expression by transduction and subsequent whole cell patch 
clamp of CHO cells (Figure 33) stably expressing the coxsackie adenovirus 
receptor (CHO-CAR cells), generously provided by Dr. Jeffrey Bergelson at the 
University of Pennsylvania.70 CHO-CAR cells were grown at 37°C with 5% CO2 
in F-12 nutrient mixture medium supplemented with 10% fetal bovine serum 
(FBS, Atlanta Biologicals, Atlanta, GA), penicillin (50 units/ml), streptomycin (50 
μg/ml), and L-glutamine (2 mM). 0.1 or 0.01 μl of each viral prep was added to a 
35 mm dish of 60% confluent CHO-CAR in 0.5 ml media and incubated for 4 h. 
Virus was aspirated and fresh culture media was added. Retrospectively, 
adenovirus was added at an approximate multiplicity of infection (MOI) of 0.5-1.  
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Figure 32. Representative fluorescence expression in CHO-CAR cells after adenoviral 
transduction; Image: CHO-CAR cells 36 h after KCNQ1-IRES2-DsRedMST transduction, 
captured at 10x, illustrating the variable degree of fluorescence expression. Inset: Co-
transduction of CHO-CAR cells with KCNQ1-WT-IRES2-DsRedMST and KCNE1-
IRES2-eGFP captured at 40x, illustrated the fluorescence expression of red (Q1-
DsRedMST), green (E1-eGFP), and yellow (Q1-DsRedMST and E1-eGFP co-
expression). 
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Figure 33. Representative potassium currents recorded from CHO-CAR cells after 
adenoviral transduction; A, KCNQ1 tranduction alone; B, KCNQ1 + KCNE1 co-
transduction; C, S140G transduction alone; D, S140G and KCNE1 co-transduction; E, 
dsRedMST alone transduction; F, KCNE1 transduction alone. 
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After 36 h, potassium currents were recorded from fluorescent CHO-CAR cells 
using standard solutions. The extracellular solution contained in mM: 132 NaCl, 
4.8 KCl, 1.2 MgCl2, 1 CaCl2, 5 glucose, and 10 HEPES, pH 7.4. The intracellular 
solution contained in mM: 110 potassium-aspartate, 1 CaCl2, 10 HEPES, 11 
EGTA, 1 MgCl2, and 5 K2ATP, pH 7.35. Pipette solution was diluted 5-10% to 
prevent activation of swelling-activated currents. Patch pipettes were pulled from 
thick wall borosilicate glass (World Precision Instruments, Inc.) with a multistage 
P-97 Flaming-Brown micropipette puller (Sutter Instrument Co., Novato, CA) and 
heat-polished with a Micro Forge MF 830 (Narashige International USA, Inc., 
East Meadow, NY). After heat polishing, the resistance of the patch pipettes was 
2-4 megaohms in the standard solutions. A 2% agar bridge with composition 
similar to the control bath solution was used as a reference electrode. Unless 
otherwise stated, all chemicals were obtained from Sigma-Aldrich (St. Louis, 
MO). 
 
Whole-cell currents were recorded at room temperature (20–23°C) using an 
Axopatch 200B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Test 
pulses were generated using Clampex 9.1 (MDS Analytical Technologies), and 
whole-cell currents were acquired at 5 kHz and filtered at 1 kHz. The access 
resistance and apparent membrane capacitance were estimated as described 
previously.8 Whole-cell currents were not leak subtracted. Junction potentials 
were zeroed with the filled pipette in the bath solution. All recordings were started 
4 min after achieving a whole cell patch. Whole-cell currents were measured 
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during a series of 2 s voltage steps from a holding potential of −80 mV to test 
potentials ranging from −80 to +60 mV (in 10 mV increments) followed by a 1 s 
step to −30 mV to record tail currents with a 20 s interpulse duration. 
Representative images of fluorescent CHO-CAR cells (Figure 32) and potassium 
channel currents (Figure 33) were obtained for all viral preps to confirm subunit 
and marker expression. 
 
Adenoviral titer 
After confirmation of virus expression, viral titer was determined using the tissue 
culture infective dose 50 (TCID50) method as described for the AdenoVator
TM 
Vector System (QBioGene, Carlsband, CA) (Figure 34). For multiplicity of 
infection (MOI) calculations, titers were converted to plaque forming units (PFU) 
by the following equation: PFU = 0.69*TCID50. The titers achieved ranged from 
109 to 1010 PFU/ml.  
 
Rabbit left atrial myocyte isolation 
Left atrial myocytes were isolated from hearts of male New Zealand White rabbits 
(6-7 lbs from Charles River Canada), using the method of Bassani, et al.50 with 
modifications. Briefly, rabbits were sedated with intramuscular acepromazine and 
then anesthetized with intravenous pentobarbital sodium. Hearts were excised 
quickly and arrested on ice for 5 minutes in nominally calcium-free minimum 
essential medium solution (MEM, Joklik modification). Hearts were Langendorf 
perfused at 37°C for 10-15 min in the same MEM solution gassed with 95% O2  
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Figure 34. Typical results of tissue culture infective dose 50 (TCID50) adenoviral titering 
method with calculation explanation. CPE indicates cytopathic effect, in which any 
portion of the well demonstrates cell death as compared to the control wells. Adapted 
from AdenoVator.  
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and 5% CO2. During initial perfusion, the pulmonary vessels were closed with 
microvessel clips to perfuse both atrial chambers at high pressure, and the atrial 
chambers were punctured twice at their apex to facilitate flow-through. Then the 
perfusion was switched to MEM solution containing 0.05 mg/ml Liberase TH 
(Roche Applied Sciences, Indianapolis, IN). After 5 min of enzymatic digestion, a 
small incision was made in the left ventricle in the area between major coronary 
vessels. Serial tissue samples (30 s - 1 min) were taken from this incision with 
fine tweezers and inspected immediately by light microscopy. When the majority 
of ventricular myocytes released were quiescent rods (7-20 min), the left atrium 
was removed from the heart, the remaining heart was removed from the 
Langendorf apparatus, and left atrium was recannulated on the Langendorff 
apparatus. Serial samples were taken from the perfused atrium until the sample 
edges contained packets of rod-shaped atrial myocytes and the majority of 
released atrial myocytes were quiescent rods (5-20 minutes). The left atrium was 
removed and placed in MEM solution containing 1% bovine serum albumin 
(BSA). The tissue was minced, gently triturated with a wide-bore pipette, and 
filtered through a 100 μm cell strainer (BD Biosciences, San Jose, CA) into a 50 
ml conical tube. The myocytes were allowed to settle into a soft pellet by gravity 
for 30 – 60 min at room temperature. Then the supernatant was aspirated, and 
atrial myocytes were resuspended in fresh BSA solution. Myocytes were plated 
on laminin-coated glass coverslips, and incubated at 37°C with 5% CO2. The 
experimental procedure for isolating rabbit cardiac myocytes was approved by 
Vanderbilt University Institutional Animal Care and Use Committee.  
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Rabbit myocyte division for electrophysiology & storage 
For three rabbit myocyte isolations, left and right atria were divided into 9 regions 
(Figure 35). These regions plus the septum were divided. One-quarter was 
minced, triturated, and plated for electrophysiological experiments and culture. 
The remaining three-quarters was placed in a screw-capped cryovial, labeled 
with region, and flash frozen in liquid nitrogen. The labels indicated atrial septum 
or right or left atria (R or L), anterior, middle, or posterior orientation (A, M, P), 
and upper, middle, lower area (U, M, L) for a total of 19 regions per rabbit heart 
atria. In addition, samples of the apical and basal regions of the left and right 
ventricle and interventricular septum were stored in labeled cryovials and flash 
frozen in liquid nitrogen. All vials were stored at -80°C .  
 
Atrial myocyte culture and adenoviral transduction 
Three hours after termination of enzymatic digestion, myocytes were placed into 
culture media consisting of MEM supplemented with Hank’s salts, 2 mM L-
glutamine (Gibco-Invitrogen, Life Technologies, Grand Island, NY), insulin-
transferrin-selenium-X supplement (Gibco-Invitrogen, Life Technologies, Grand 
Island, NY), penicillin (50 units/ml), streptomycin (50 μg/ml), 1% bovine serum 
albumin, 5 µM blebbistatin at pH 7.4 (modified from Kabaeva, et al. 2008)52. In 
some experiments, 6 h post isolation atrial myocytes cultures were paced at 1, or 
3 Hz pacing frequency using C-Dish culture dish 4-well electrode and C-Pace EP 
Culture Pacer (IonOptix LLC, Milton, MA). Pacing decreased the number of 
viable at 48 h by approximately 50% compared to non-paced cultures. 
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Figure 35. Atrial regional divsions for electrophysiology and -80°C tissue library. A, 
whole heart orientation of the left atria and C of the right atria. Example left (B) and right 
(D) atria prior to divisions in the same orientation as whole heart images. Dotted lines 
indicate division lines to be cut with scissors. Labels indicate regional nomenclature.  
Green * indicate regions from which potassium currents were recorded. 
  
94 
 
To optimize viral transduction of atrial myocytes, virus was added to the 
myocytes at a MOI of 1-2,000 immediately after plating in culture media to    6 h 
post-isolation. Virus was incubated with myocytes for various durations (3 h,     6 
h, 12h, 24 h, 36 h, and 48 h). Best expression was achieved after 40 h incubation 
with an MOI of 2000 added immediately after plating (Figure 3.5). To express 
WT-IKs, adenoviruses Ad5-KCNQ1-DsRedMST and Ad5-KCNE1-eGFP were 
used to co-infect myocytes, whereas S140G-IKs was generated by co-infecting 
myocytes with adenoviruses Ad5-S140G-DsRedMST and Ad5-KCNE1-eGFP. 
Ad5-dsRedMST infection was used for vector only controls. Infected myocytes 
were cultured at 37°C in 5% CO2 and used for electrophysiology experiments 
starting at 40 hours post-isolation. The efficiency of dual transduction of healthy-
appearing (striated, rod-shaped) myocytes was approximately 15-20%.  
 
Voltage clamp electrophysiology 
Potassium currents were recorded from adult rabbit atrial myocytes cells using 
the whole-cell configuration of the patch clamp technique.55 The extracellular 
solution contained in mM: 137 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 
HEPES, 0.05 CdCl2, pH 7.4. In experiments with drug application, bath solution 
containing vehicle (<0.01% dimethyl sulfoxide) or HMR-1556 (1 nM - 2 μM) was 
applied by pencil perfusion using the Automate Valve-link perfusion system. 
HMR-1556 ((3R,4S)-(+)-N-[-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy) 
chroman-4-yl]-N-methyl-ethanesulfon-amide), was synthesized by the  
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Figure 36. Adenoviral transduction of adult rabbit left atrial myocytes after 52 hours in 
culture. Representative bright field (A-C) and fluorescent (D-F) images of the same atrial 
myocytes. Myocytes were transduced with Ad-S140G-dsRedMST (A,D), Ad-KCNE1-
eGFP (B,E), or both Ad-S140G-dsRedMST and Ad-KCNE1-eGFP (C,F). 
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Vanderbilt Institute of Chemical Biology Synthesis Core using a published 
method.71 In experiments with β-adrenergic stimulation, 1 μM or 10 μM 
isoproterenol and 250 or 1 mM 8-bromo-cAMP were applied by pencil perfusion 
for 1-10 minutes. Isoproterenol was freshly prepared prior to each use. 8-bromo-
cAMP was used from -20°C frozen stocks at 100 mg/ml in dH2O, prepared in low 
light conditions. All solutions with 8-bromo-cAMP were covered with aluminum 
and experiments were conducted in low light conditions. The standard 
intracellular solution contained in mM: 110 K-glutamate, 10 KCl, 10 NaCl, 14 
EGTA, 5 HEPES, 2 CaCl2, 5 Mg-ATP, pH 7.2. Pipette solution was diluted 5-10% 
to prevent activation of swelling-activated currents. In experiments with pipette 
applied factors, 250 μM 8-bromo-cAMP or 10 μM phosphatidylinositol 4,5-
bisphosphate (PIP2) were added to the pipette solution. PIP2 was prepared from 
1 mg/ml stock chloroform/methanol/water solution, stored at -20C, as provided by 
manufacturer (Avanti Polar Lipids, Inc Alabaster, AL). PIP2 solution (10 μl) was 
added to a glass test tube and the solution was allowed to evaporate (<5 mins). 
Then, 1 ml pipette solution was added to PIP2 and the tube was sonicated for 30 
mins prior to use for patch clamp.  
 
Patch pipettes were pulled from thick wall borosilicate glass (World Precision 
Instruments, Inc.) with a multistage P-97 Flaming-Brown micropipette puller 
(Sutter Instrument Co., Novato, CA) and heat-polished with a Micro Forge MF 
830 (Narashige International USA, Inc., East Meadow, NY). After heat polishing, 
the resistance of the patch pipettes was 2-4 megaohms in the standard solutions. 
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A 2% agar bridge with composition similar to the control bath solution was used 
as a reference electrode. Unless otherwise stated, all chemicals were obtained 
from Sigma-Aldrich (St. Louis, MO). 
 
Whole-cell currents were recorded at room temperature (20–23°C) using an 
Axopatch 200B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Test 
pulses were generated using Clampex 9.1 (MDS Analytical Technologies), and 
whole-cell currents were acquired at 5 kHz and filtered at 1 kHz. The access 
resistance and apparent membrane capacitance were estimated as described 
previously.56 Whole-cell currents were not leak subtracted. Junction potentials 
were zeroed with the filled pipette in the bath solution. All recordings were started 
4 min after achieving a whole cell patch.  
 
Whole-cell potassium currents were measured during a series of 2 s voltage 
steps from a holding potential of −80 mV to test potentials ranging from −80 to 
+60 mV (in 10 mV increments) followed by a 1 s step to −30 mV to record tail 
currents with a 20 s interpulse duration.  
 
Current clamp recording 
Action potentials were elicited from atrial myocytes using the whole-cell 
configuration of the patch clamp technique55 and previously described 
solutions.58 The extracellular solution contained in mM: 140 NaCl, 5.4 KCl, 1 
MgCl2, 1 CaCl2, 7.5 glucose, 0.33 NaH2PO4, and 5 HEPES, pH 7.4. The 
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intracellular solution contained in mM: 120 KCl, 10.25 NaCl, 5 MgCl2, 0.36 CaCl2, 
5 HEPES, 5 EGTA, 5 creatine phosphate (Tris), 5 glucose, and 5 K2ATP, pH 7.2. 
Patch pipettes were pulled from thick wall borosilicate glass (World Precision 
Instruments, Inc., Sarasota, FL) with a multistage P-97 Flaming-Brown 
micropipette puller (Sutter Instrument Co., Novato, CA) and heat-polished with a 
Micro Forge MF 830 (Narashige International USA, Inc., East Meadow, NY). 
After heat polishing, the resistance of the patch pipettes was 1.5-2.5 megaohms 
in the above solutions. A 2% agar bridge with composition similar to the control 
bath solution was used as a reference electrode.  
 
Action potentials were elicited at room temperature (20–23°C) using an Axopatch 
700B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Pulses were 
generated using Clampex 9.1 (MDS Analytical Technologies), and action 
potentials were acquired at 10 kHz. No current was injected to maintain resting 
membrane potentials. To elicit action potentials, a stimulus threshold was 
determined for each myocyte, using a protocol of 0.1 nA steps of 3-4 ms 
duration. The stimulus used for experiments was approximately The stimulus 
was used to elicited action potentials at 0.1 Hz for 5 mins for an equilibration 
period. Then, action potentials were elicited for 3 min each at 0.25 Hz, 0.5 Hz, 
and 1 Hz.  
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Current clamp data analysis 
Data were collected for each experimental condition from at least three separate 
myocyte isolations and analyzed using a combination of Clampfit 9.1 (MDS 
Analytical Technologies) and Excel 2007 (Microsoft). Data were transferred from 
Clampfit to Excel with each recording frequency for each myocyte contained in a 
separate file. The first column of the file contained the time in msec in 0.1 msec 
increments. The subsequent columns contained the value, in mV, recorded 
during each stimulus and elicited action potential. Each column represented a 
stimulated action potential recording. Each file contained all action potentials 
recorded over the 3 min recording period. With assistance from Jonathan 
Campbell (MSOR candidate at SMU), a Visual Basic for Applications (VBA) 
program in Excel was written to read each file and to determine for each 
recorded action potential the following parameters: resting membrane potential, 
amplitude, overshoot, and action potential duration at 20% (APD20), 50% 
(APD50), and 90% (APD90) (Figure 37). Depending on the number of files, this 
analysis program could take well over 2 hours to run.  
 
Key mathematical functions in Excel allowed for the rapid determination of each 
of these parameters for high-throughput analysis (simplified examples in Figure 
38). The average function was used to determine the resting membrane potential 
(RMP) in mV, defined as the average value observed 10 ms prior to the stimulus. 
The overshoot was defined as the highest value after the current stimulus. The 
max function was used to determine the overshoot. The amplitude  
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Figure 37. Illustration of action potential analysis parameters on an example atrial action 
potential recording.  
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of the action potential, defined as the total height of the AP, was determined as 
the overshoot minus the resting membrane potential. The index function was 
critical to determining the action potential duration (APD). The APD was defined 
as time from the action potential overshoot to the return to RMP. Using the index 
and match functions, we first determined the time to overshoot. The index 
function provides the value from an index when the range value matches your 
defined parameter, using the match function. Here, the index is the time column 
in msec, the range is the action potential trace, and the value to match is the 
overshoot. The index function will return the time value from the same row as the 
overshoot value in the trace designated. The $ symbols are used to maintain 
same index row and column as the function is copied over the worksheet. Then, 
the duration for 90% repolarization is determined. Ninety percent repolarization is 
equal to the overshoot value minus 90% amplitude. Because there will be two 
points on the trace equal to this value (during AP upstroke and during AP 
repolarization), the range is limited to after the overshoot value. The index 
function will return the time at which 90% repolarization is reached. Then the 
overshoot time is subtracted to get the APD90 value. A simplified example of this 
function is illustrated in Figure 38.  
 
All parameters determined were placed in a new Excel file organized by 
recording file name and trace number (Figure 39). To assess accuracy, 
parameters for randomly selected action potentials in each recording were 
verified manually using Clampfit. This master data list was copied into another  
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Figure 38. Example calculation of action potential parameters using Excel functions. 
Specifically, APD90 is calculated using the Index and Match formula functions.  
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Figure 39. Data analysis of VBA analysis program parameters using the Excel 
AverageIfs function. In this example, the amplitude values in the Selected Data 
Worksheet are averaged if the file name in the Selected Data worksheet matches the file 
name in the Analysis Worksheet.  
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worksheet. This new worksheet was then filtered to include or exclude certain 
parameters, such as RMP below -40 mV or amplitude >10 mV to exclude traces 
where the cell is too depolarized or an AP fails to be stimulated. Alternatively, the 
file could be culled to only included, for example, the first trace or the last 10 
traces from each recording. To analyze this selected dataset, a new worksheet 
was created and utilized the AverageIfs function (note that this functions requires 
Excel2007 or later versions). For example, to average all of the amplitudes for a 
certain file in your analysis worksheet, the amplitude column is designated in the 
selected data worksheet but the values are only averaged if the file name column 
equals file name in your analysis worksheet (Figure 39). Once created, this 
AverageIfs-based analysis worksheet can remain the same and be used with 
different selected datasets. Together, this program and analysis method allow for 
powerful, thorough analysis of action potential data.  
 
This action potential trace-by-trace parameter determination gives one the 
opportunity to analyze trends in the action potential over time. To visualize these 
trends, we added the automated creation of graphs to the VBA program (Figure 
40). These graphs also served as another measure of quality control. The first 
graph plotted the last recorded action potential trace. The second graph 
generated plotted the amplitude, overshoot, resting membrane potential, and a 
value called 'seal'. Seal was a value in the middle of the stimulus pulse; a rise in 
this value over the course of a recording indicated a closing of the whole cell seal   
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Figure 40. VBA analysis program generated graphs. Example graph illustrates VBA 
program determined parameters  for action potentials elicited at 1 Hz for 3 min recorded 
from adenovirally transduced, S140G-IKs expressing adult rabbit atrial myocyte. A, Last 
action potential recorded; B, Amplitude, resting membrane potential, overshoot peak, 
and seal values by trace number; C, APD20, APD50, and APD90 by trace number; D, Ratio 
of APD20 to APD90 by trace number.   
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(see Figure 21). Aberrations in any of these measurements could indicate a 
number of disruptions or issues in the current clamp recording: loss of recording 
seal integrity, hypercontraction of the myocyte, stimulus failing to elicit an AP, or 
triggered activity. One example of triggered activity is an EAD that extends over 
one trace into the next (Figure 41). The Clampfit recording in a trace view would 
give a view of what looks like recording disruption. However, continuous view 
allows the visualization of an EAD that extends over multiple traces. In the graph, 
the resting membrane would register as elevated, the trace amplitude would be 
much shorter, and the seal value would be much higher. The third graph 
illustrates the APD20, APD50, APD90 over time. This visualization of the APDs 
allows determination of when the steady-state APD is achieved as well as the 
variations from AP to AP. In the fourth graph, the APD20 to APD90 ratio is 
illustrated. This ratio of often used to quantify the AP morphology. In addition to 
visualization of trends over time, any abnormal values are highlighted in these 
graphs. This awareness triggers investigation of the original Clampfit recording 
and inquiry into the inclusion those traces in the data analysis.  
 
For the analysis in this chapter, the parameters were averaged for the last 10 
recorded action potentials in each experimental condition. Differences between 
two groups were assessed using unpaired Student's t test. Statistical tests were 
performed using SigmaStat 2.03 (Systat Software, Inc.).  
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Figure 41. Single trace view versus continuous view of an early-after-depolarization 
(EAD). Upper panel: Trace view can mask an EAD that extends over multiple traces. 
The start of the EAD is shown in red. Lower panel: Continuous view clearly illustrates the 
full extent of the EAD.  
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Results 
 
Absence of endogenous HMR-1556 sensitive K+ current in adult rabbit atrial 
cardiac myocytes 
To determine the baseline IKs levels in rabbit atrial myocytes, whole-cell voltage 
clamp experiments were conducted. We recorded total potassium current levels 
and then applied the IKs-specific blocker, HMR-1556. With digital subtraction, we 
determined the levels of HMR-1556 sensitive current. Initially, we recorded 
potassium currents 3 days post-isolation to mimic a post-viral transduction time 
point. However, no HMR-1556 sensitive current was recorded. Because some 
ionic currents are down-regulated over time in tissue culture, and electrical 
stimulation during culture has been shown to mitigate this effect, we electrically 
paced our atrial cultures at 3Hz; no HMR-1556 sensitive current was recorded. 
Notably, assessing myocyte pacing capture was difficult due to the presence of 
excitation-contraction upcoupler, blebbistatin, in the media. Further, many 
myocytes did not survive pacing. To assess whether difficulties measuring 
current were due to culture conditions, we measured potassium currents from 
atrial myocytes 3 h, 24 h, and 48 h post-isolation and were unsuccessful in 
recording HMR-1556 sensitive current (Figure 42). These data suggest that 
under baseline voltage clamp conditions, 1 μM HMR-1556-sensitive potassium 
current is not activated in rabbit atrial myocytes. 
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Figure 42. Absence of HMR-1556 sensitive potassium current in adult rabbit atrial 
myocytes over time. Representative HMR-1556 sensitive potassium current recorded 
from adult rabbit atrial myocytes from 3 hsr to 72 h post-isolation. Standard activation 
protocols were used to record potassium currents from  vehicle treated myocytes and 
myocytes after 1 min application of 1 μM HMR-1556.HMR-1556 sensitive current was 
determined by digital subtraction of HMR-1556 treated from vehicle treated recordings. 
A, 3 h; B, 24 h; C, 48 h, and D, 72 h after atrial myocyte isolation.   
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We sought to activate endogenous IKs in rabbit atrial myocytes through β-
adrenergic stimulation and phosphatidyl-inositol 4,5-bisphosphate PIP2 
enhancement. Studies in heterologous systems have demonstrated that cAMP-
mediated PKA-phosphorylation of Ser27 on KCNQ1 N-terminus enhances IKs 
current density.6 First, we applied 1 μM or 10 μM of freshly prepared 
isoproterenol, a β-adenoreceptor agonist, to the bath. We also added 1 μM 
isoproterenol to the myocyte culture media and incubated the cells overnight. 
This overnight isoproterenol exposure induced rapid contraction in a subset of 
atrial myocytes. However, no HMR-1556 sensitive current was recorded with any 
form of isoproterenol stimulation. As an alternative to isoproterenol stimulation, 
we used 8-bromo-cAMP, a cell permeable analog of cAMP and activator of 
protein kinase A, a downstream effector of β-adrenergic stimulation. Neither 250 
μM or 1 μM 8-bromo-cAMP induced HMR-1556 sensitive current or increases in 
potassium current density. Although 8-bromo-cAMP is membrane permeable, we 
also added it to the intracellular solution; no HMR-1556 sensitive current was 
induced. Phosphatidyl-inositol 4,5-bisphosphate (PIP2) is a phospholipid and 
known activator of IKs.
7, 8 We added PIP2 to the pipette solution to stimulate IKs; 
yet again no HMR-1556 sensitive current was induced. Together, these data 
suggest that endogenous HMR-1556 sensitive current is not present in rabbit 
atrial myocytes under these recording conditions. 
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Given the documented heterogeneity in recorded IKs current in adult rabbit 
ventricular myocytes,72 we hypothesized that a similar regional heterogeneity 
may exist in rabbit atrial myocytes. The rabbit atria were divided into 19 regions 
and potassium currents from at least 3 atrial myocytes in 7 non-adjacent regions 
were recorded during superfusion of 10 μM isoproterenol (Figure 35). While 
morphological differences were noted with regards to cell size, none of these 
regions had enhanced HMR-1556 sensitive current.  
 
Variable HMR-1556-sensitive current with viral transduction of KCNQ1, 
S140G, or KCNE1 subunits 
Although endogenous HMR-1556 sensitive current was not detected, KCNQ1 
and/or KCNE1 may be expressed in rabbit atrial myocytes, yet not together to 
result in HMR-1556 sensitive IKs. To determine whether KCNQ1 subunit was 
expressed, we transduced rabbit atrial myocytes with adenovirus encoding 
KCNE1. With viral-KCNE1 expression, 50-100 pA of HMR-1556 sensitive current 
was detected in all atrial myocytes examined. In addition, compared to non-
transduced myocytes a decrease in the initial peak current density was noted. 
These data suggest that KCNE1 expression augments a low level of endogenous 
KCNQ1 and likely alters other potassium channels in rabbit atrial myocytes. The 
decrease in peak current density suggests alterations to ITO, but without using 
ITO-specific blockers this possibility is speculative. 
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Conversely, to establish whether the KCNE1 subunit was expressed in rabbit 
atrial myocytes, we transduced rabbit atrial myocytes with either adenovirus 
encoding KCNQ1 or S140G. Compared to dsRedMST vector-only transduced 
myocytes, a significantly greater late K+ current density was observed with either 
KCNQ1 or S140G expression. However, in approximately half of the myocytes 
did this increase result in measureable 1 μM HMR-1556 sensitive current (Figure 
43). The non-HMR-1556 sensitive increase likely is due to KCNQ1 current alone. 
The variable recording of HMR-1556 sensitive current suggests heterogeneous 
expression of endogenous KCNE1.  
 
Together, these electrophysiological data with viral KCNQ1 or KCNE1 subunit 
expression suggests a low level of endogenous KCNQ1 expression in most atrial 
myocytes and non-uniform expression of KCNE1. Verification using other 
modalities such as mRNA or protein expression levels would be vital to 
supporting this observation. Importantly, these data do not rule out a 
subpopulation of atrial myocytes with HMR-1556 sensitive current. However, to 
assess the effects of S140G-IKs or KCNQ1-IKs on an atrial action potential, both 
subunits will need to be expressed. Indeed, dual transduction with S140G and 
KCNE1 adenovirus results in consistent HMR-1556-sensitive potassium current.  
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Figure 43. HMR-1556 sensitive potassium current is not consistently measured in 
KCNQ1-WT and KCNQ1+S140G expressing rabbit atrial myocytes. Representative 
traces of rabbit atrial myocyte potassium currents (above) and HMR-1556 sensitive 
potassium currents (below) with KCNQ1-WT expressed in A and B; S140G-WT 
expressed in C and D. 
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S140G-IKs induces triggered activity at low frequency and shortens action 
potential duration at high frequency stimulation 
Having established that dual adenoviral transduction of KCNQ1 or S140G and 
KCNE1 is needed to produce reliable HMR-1556 sensitive current, we explored 
the effects of exogenous IKs on adult rabbit atrial action potentials. First, atrial 
myocytes were transduced with vector-only controls (adenoviruses expressing 
only dsRedMST). However, recording from these myocytes in the current clamp 
configuration was very difficult. A gigaohm seal and subsequent whole cell were 
obtained in <5% of myocytes. The resting membrane potentials often were 
significantly depolarized (-30 mV to -20 mV). In cells in which a good whole cell 
seal was achieved, the action potentials were initially generated spontaneously 
and later the myocytes failed to fire even with stimulus (Figure 44). No action 
potentials could be obtained past the 5 min equilibration period. With adenovirus 
expressed WT-IKs and S140G-IKs, the whole cell seal could be achieved reliably 
with 40-60% efficiency. At low frequency action potential stimulation (0.1 or 0.25 
Hz), 46% of atrial myocytes transfected with S140G-IKs displayed abnormal 
action potential morphology in at least one stimulated action potential (Figure 
45). Unexpectedly, this morphology typically had a prolonged action potential 
duration (APD) with hallmarks of a precursor early after depolarization (EAD) (a 
bump), yet rarely was a full EAD with second upstroke triggered. Further, during 
these low frequency recordings, 27% of myocytes expressing S140G-IKs fired at 
least one spontaneous action potential. In the WT-IKs controls, no abnormal   
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Figure 44. Representative trace of spontaneous activity and subsequent membrane 
depolarization over 90 s in dsRedMST-expressing adult rabbit left atrial myocytes at 40 h 
post-isolation. This depolarization likely results from changes in ion channel expression 
resulting from prolonged tissue culture. 
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Figure 45. Representative abnormal action potential morphology in a myocyte 
expressing S140G-IKs. From action potentials elicited at low frequencies of either 0.1 Hz 
or 0.25 Hz, 46% of myocytes expressing S140G-IKs demonstrated abnormal morphology 
with a bump during repolarization, but not second upstroke of a full EAD compared to 
0% WT-IKs.  
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morphology or triggered activity was seen in any frequency recordings. When 
paced at faster frequencies (0.5 or 1 Hz), cells expressing S140G-IKs had a 
significantly shorter action potential duration compared to WT-IKs expressing 
atrial myocytes (Figure 46). Further, S140G-IKs induced rate dependent APD 
shortening at 1 Hz compared to 0.25 Hz (see Table 9). WT-IKs expressing 
myocytes had no significant difference in rate dependent APD. Overall, 
expression of S140G-IKs significantly hyperpolarized the resting membrane 
potential of the atrial myocytes compared to WT-IKs expression (S140G-IKs: -70.5 
±2.2 mV; WT-IKs -60.5 ± 3.5 mV). Together, S140G-IKs expression in rabbit atrial 
myocytes results in increased triggered activity at low frequency and both rate-
dependent and subunit-specific shortening of APD at high frequency stimulation. 
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Figure 46 S140G-IKs expression shortens the action potential duration in adult rabbit 
atrial myocytes at 40 h post-isolation. Representative action potentials expresses WT-IKs 
(black) or S140G-IKs (blue). 
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Table 9. Action potential duration in rabbit atrial myocytes expressing WT-IKs and 
S140G-IKs 
 
 Hz n APD20 APD50 APD90 
WT-IKs 0.25 11 206.3 ±52.4 289.8 ± 67.8 532.4 ± 88.6 
S140G-IKs 0.25 13 137.2 ± 41.3 234.8 ± 66.4 374.8 ± 80.7
# 
WT-IKs 0.50 10 216.3 ± 42.5 307.9 ± 51.0 542.3 ± 66.5 
S140G-IKs 0.50 12 70.3 ± 18.0* 130.8 ± 25.6* 236.9 ±40.2* 
WT-IKs 1.00 10 235.9 ± 30.3 328.4 ± 33.2 538.6 ± 48.8 
S140G-IKs 1.00 12 62.43 ± 14.1* 106.8 ± 21.8* 212.9 ± 33.4* 
 
* p<0.01 compared to WT-IKs of same frequency 
# p<0.05 compared to 1 Hz S140G-IKs 
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Discussion 
The discovery of monogenic causes of familial atrial fibrillation has provided an 
opportunity to investigate AF substrate susceptibility outside of the many 
contributory factors involved in the generation of secondary atrial fibrillation. 
Here, we advance the insights garnered from monogenic characterization of AF 
mutations in heterologous systems and mathematical model by investigating 
S140G-IKs expression in a native atrial myocyte model system. We developed 
methods for adenoviral expression of S140G-IKs and computer analysis of action 
potential parameters in a high throughput fashion. There are limitations to this 
computational analysis and opportunities to improve its utility. Specifically, 
triggered activity is not well recognized. The program is written to only recognize 
one action potential per trace. Delayed-after-depolarizations (DADs) are missed 
by this automated analysis. Further, early-after-depolarizations (EADs) are not -
seen as a single event when they extend over multiple traces. Nevertheless, it 
allows trace-by trace analysis in a high throughput manner not possible in a short 
time scale with manual analysis. Using these methods, we demonstrated that 
S140G-IKs shortened APD and increased triggered activity in rabbit adult atrial 
myocytes.  
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Overcoming critical issues in methods was key for our studies. Exogenous 
expression of potassium channels in adult rabbit atrial myocytes was enabled by 
using a modified CMV promoter, using a very high titer, and an extended 
infection period to elicit expression. In addition, we developed a VBA-based 
computer program for the high-throughput analysis of action potential recordings. 
This program allowed for analysis of all action potential recorded and rapid 
analysis of multiple stimulation frequencies rather than only a small subset of 
APs typically described. Collectively, these methods greatly facilitated these 
investigations. 
 
Our results demonstrate that under our recording conditions, rabbit atrial 
myocytes do not have endogenous HMR-1556 sensitive current expressed 
acutely or over time in culture. Further, attempts to stimulate endogenous IKs 
adrenergically or with the addition of PIP2 failed to produced HMR-1556 sensitive 
current. Electrophysiological recordings with either KCNE1 or KCNQ1 subunit 
adenoviral expression suggest that most rabbit atrial myocytes likely have a low 
level of KCNQ1 expression and variable expression of KCNE1. Thus to reliably 
generate WT-IKs or S140G-IKs, we co-transduced rabbit atrial myocytes with 
KCNQ1 and KCNE1 subunits. The lack of HMR-1556 sensitive current in an 
electrophysiological survey is not unexpected but does not rule out IKs expression 
in rabbit atrial myocytes. In the literature, rabbit atrial myocytes are not well 
characterized. Potassium currents underlying IKs are similarly under studied in 
these cells. Given the heterogeneity of IKs expression in ventricular myocytes, a 
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more precise and thorough regional analysis may yield a more complete 
expression picture. Determining regional mRNA or protein levels of IKs may 
elucidate any regional enhancement and give a more complete picture to better 
target electrophysiological studies. Despite the lack of endogenous IKs, rabbit 
atrial myocytes still provide a more human-like native atrial myocyte milleau in 
which to investigate the effects of S140G-IKs expression.  
 
Action potential recordings revealed that S140G-IKs expression compared to WT-
IKs expression hyperpolarized the resting membrane potential, and shortened 
action potential duration at higher frequencies. Further S140G-IKs demonstrated 
frequency dependent APD abbreviation not noted in WT-IKs. These data are 
consistent with the AP effects predicted from the electrophysiological properties 
of S140G-IKs observed in heterologous system experiments. The constitutively 
active channel would contribute to hyperpolarizing the membrane, activation 
during the short atrial AP, and current accumulation during more rapid activation 
given the very delayed deactivation kinetics. WT-IKs is hypothesized to have a 
minimal role the APD of the atrial considering its slowed activation profile. Even 
with the prolonged atrial APD observed here at room temperature, over the 
course of 0.5 s WT-IKs would still be minimally activated. In heterologous 
systems, most activation pulses used are 2 sec long to observe WT-IKs activation 
with few channels open at 0.5 s time point. Moreover, without β-adrenergic 
stimulation, WT-IKs current density would not be predicted to increase 
dramatically in response to more frequent simulation. Unexpectedly, we 
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observed EAD and full triggered beats at lower frequency in myocytes 
expression S140G-IKs. A shortened action potential in an isolated myocyte is not 
predicted to have spontaneous triggered activity, but yield a substrate more 
susceptible to triggers within the atrial tissue. This unanticipated results suggests 
that S140G-IKs expression results in alteration of calcium dynamics that at low 
frequencies can results in this observed triggered activity. How this alteration 
might occur is not readily explained and needs further investigation.  
 
An important limitation of this study is that while we are using a native atrial 
myocytes to investigate the effects of S140G-IKs, the 40+ h of cell culture, 
adenoviral expression levels, and electrophysiological recording conditions at 
room temperature introduce many non-native components that could alter the 
results. Nevertheless, using this system allows us to answer questions in a closer 
to human native atrial myocyte environment than in heterologous system or even 
transgenic mouse models. In summary, we demonstrate that S140G-IKs 
expression in rabbit atrial myocytes shortens APD and increases triggered 
activity while hyperpolarizing the resting membrane potential.   
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CHAPTER IV 
 
SELECTIVE TARGETING OF GAIN-OF-FUNCTION KCNQ1 MUTATIONS 
PREDISPOSING TO ATRIAL FIBRILLATION 
 
Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults. 
The prevalence of AF rises exponentially with age, and because of the aging 
population, the number of persons with AF in the United States is projected to 
increase to 12 million by 2050.1 Importantly, AF confers a 6-fold increased risk for 
thromboembolic disease including stroke, predisposes to heart failure and is 
associated with premature death.27 The incremental healthcare costs directly 
related to the diagnosis and management of AF in the United States have been 
estimated at $6 billion.28  
 
Most often, AF occurs within the context of structural heart disease with onset 
past the age of 65 years. However, an estimated 10-30% of AF, designated as 
lone AF, arises in the absence of overt heart disease and has a younger age of 
onset.29-32 Genetic predisposition to AF has been demonstrated in populations33, 
34 and in families with monogenic forms of the disease.35 AF-associated 
mutations have been identified in potassium channels,2, 15, 38, 39, 73, 74 sodium 
channels,41-43 and other genes.21 The mutation KCNQ1-S140G was the first 
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identified mutation and remains the best-studied genetic variant associated with 
autosomal dominant AF.2, 16, 17, 25  
 
KCNQ1 encodes a pore-forming voltage-gated potassium channel (Kv7.1 or 
KCNQ1) that combines with the auxiliary subunit KCNE1 to generate the slow 
component of the delayed rectifier potassium current (IKs), critical for cardiac 
action potential repolarization. Co-expression of KCNQ1-S140G with KCNE1 
(S140G-IKs) demonstrated a gain-of-function with larger and more instantaneous 
current activation.2, 17 A similar gain-of-function effect occurs with the AF-
associated mutation KCNQ1-V141M.15 These in vitro data are consistent with the 
notion that increased repolarizing potassium current evoked by these mutations 
cause shortening of atrial action potentials in myocytes and an abbreviated 
effective refractory period in atrial tissues, resulting in an increased probability of 
reentry circuits and AF.17  
 
We hypothesized that KCNQ1 gain-of-function mutations have pharmacological 
properties distinct from the WT channel that may enable selective inhibition of 
mutant channel complexes. Pharmacological targeting of this gain-of-function 
behavior would be predicted to decrease AF susceptibility in persons with this 
dominant mutant allele. We tested this hypothesis using the chromanol 293B 
derivative HMR-1556, a highly specific IKs blocker when used at low 
concentrations.71, 75 Here we present evidence that S140G-IKs and V141M-IKs 
exhibit enhanced sensitivity to HMR-1556 due to an additional high affinity state. 
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Using a concentration that predominantly inhibits the high affinity state, HMR-
1556 effectively suppressed S140G-IKs amplitudes to levels not different from 
WT-IKs, attenuated the use-dependent accumulation of current without significant 
effects on WT-IKs, and mitigated action potential shortening in cultured adult 
rabbit left atrial myocytes without affecting WT-IKs action potential duration. 
These data suggest a potential opportunity for genotype-specific treatment of 
familial AF. 
 
Methods 
 
Plasmids and heterologous expression 
Human KCNQ1 and KCNE1 cDNAs were generated as described previously.3 
The S140G and V141M mutations were engineered in KCNQ1 using 
QuikChange mutagenesis (Stratagene Corp, La Jolla, CA). For experiments 
comparing heteromeric channel complexes consisting of only one KCNQ1 allele, 
cells were transiently transfected with KCNE1-IRES2-eGFP and either KCNQ1-
IRES2-DsRedMST (WT-IKs) or S140G-IRES2-DsRedMST (S140G-IKs). For 
expression of V141M-IKs, cells were co-transfected with KCNE1-IRES2-
DsRedMST and V141M-IRES2-eGFP plasmids. To study heteromeric channel 
complexes with both WT and mutant (S140G) KCNQ1 subunits, WT-IKs was 
expressed in cells transfected with KCNE1-IRES2-CD8, KCNQ1-IRES2-eGFP 
and KCNQ1-IRES2-DsRedMST whereas HET-IKs was reconstituted by 
transfecting cells with KCNE1-IRES2-CD8, KCNQ1-IRES2-eGFP and S140G-
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IRES2-DsRedMST. The efficiency of triple transfection was approximately 1-5%. 
All constructs were verified by sequencing of the entire open reading frames. 
 
Chinese hamster ovary cells (CHO-K1, American Type Culture Collection, 
Manassas, VA) were grown at 37°C with 5% CO2 in F-12 nutrient mixture 
medium supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, 
Atlanta, GA), penicillin (50 units/ml), streptomycin (50 μg/ml), and L-glutamine (2 
mM). Unless otherwise stated, all tissue culture media were obtained from Life 
Technologies (Grand Island, NY). CHO cells were transiently transfected using 
FuGENE 6 (Roche Applied Sciences, Indianapolis, IN) at a ratio of 3:1. 
 
Adenovirus generation 
Adenovirus vectors, pAd5-CMVK-NpA and pAd5-(9.2-100)delta1.6KbE3, were 
obtained from the University of Iowa Gene Transfer Vector Core (supported in 
part by the NIH and the Roy J. Carver Foundation). Using the pAd5-CMVK-NpA 
vector, we created shuttle vectors for KCNQ1-IRES2-DsRedMST, S140G-
IRES2-DsRedMST, and KCNE1-IRES2-eGFP. A modified CMV promoter was 
used for all shuttle vectors. This modified promoter consisted of the CMV 
immediate early promoter sequence immediately followed by last 358 nucleotides 
of IRES2. This modification was hypothesized to attenuate promoter efficiency 
and enabled more efficient generation of KCNQ1 encoding adenovirus.  
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Adenovirus was generated using the RAPAdTM system as previously described.54 
In brief, each shuttle vector and the backbone vector pAd5-(9.2-
100)delta1.6KbE3 were co-precipitated with calcium-chloride into human 
embryonic kidney (HEK) 293 cells in 60 mm Petri dishes. When 60% of cells had 
detached (12-14 days for KCNE1 and vector-only viruses; 17-25 days for KCNQ1 
and S140G), the cells and media were harvested, lysed through repeated 
freezing/thawing cycles, and amplified in HEK cells (typically using 5-10 150 mm 
Petri dishes). After 60% of cells detached from the large dishes (1-3 days), cells 
were pelleted by centrifugation and resuspended 5 ml of viral storage solution 
(10 mM Tris, 2 mM MgCl2, 4% sucrose, pH 8.0). Cells were then lysed and 
centrifuged. The supernatant was stored at −80°C in single use aliquots and the 
virus was used within 5 months. 
 
Viral titer was determined using the tissue culture infective dose 50 (TCID50) 
method as described for the AdenoVatorTM Vector System (QBioGene, 
Carlsband, CA). For multiplicity of infection (MOI) calculations, titers were 
converted to plaque forming units (PFU) by the following equation: PFU = 
0.69*TCID50. The titers achieved ranged from 10
9 to 1010 PFU/ml. Activity of each 
virus prep was confirmed for fluorescent marker and potassium channel 
expression by transduction and subsequent whole cell patch clamp of CHO cells 
stably expressing the coxsackie adenovirus receptor (CHO-CAR cells), 
generously provided by Dr. Jeffrey Bergelson at the University of Pennsylvania.70  
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Rabbit atrial myocyte isolation 
Left atrial myocytes were isolated from hearts of male New Zealand White rabbits 
(6-7 lbs from Charles River Canada), using the method of Bassani, et al.50 with 
modifications. Briefly, rabbits were sedated with intramuscular acepromazine and 
then anesthetized with intravenous pentobarbital sodium. Hearts were excised 
quickly and arrested on ice for 5 minutes in nominally calcium-free minimum 
essential medium solution (MEM, Joklik modification). Hearts were Langendorf 
perfused at 37°C for 10-15 min in the same MEM solution gassed with 95% O2 
and 5% CO2. During initial perfusion, the pulmonary vessels were closed with 
microvessel clips to perfuse both atrial chambers at high pressure, and the atrial 
chambers were punctured twice at their apex to facilitate flow-through. Then the 
perfusion was switched to MEM solution containing 0.05 mg/ml Liberase TH 
(Roche Applied Sciences, Indianapolis, IN). After 5 min of enzymatic digestion, a 
small incision was made in the left ventricle in an area between major coronary 
vessels. Serial tissue samples (30 s - 1 min) were taken from this incision with 
fine tweezers and inspected immediately by light microscopy. When the majority 
of ventricular myocytes released were quiescent rods (7-20 min), the left atrium 
was removed from the heart, the remaining heart was removed from the 
Langendorrf apparatus, and left atrium was recannulated on the Langendorff 
apparatus. Serial samples were taken from the perfused atrium until the sample 
edges contained packets of rod-shaped atrial myocytes and the majority of 
released atrial myocytes were quiescent rods (5-20 minutes). The left atrium was 
removed and placed in MEM solution containing 1% bovine serum albumin 
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(BSA). The tissue was minced, gently triturated with a wide-bore pipette, and 
filtered through a 100 μm cell strainer (BD Biosciences, San Jose, CA) into a 50 
ml conical tube. The myocytes were allowed to settle into a soft pellet by gravity 
for 30 – 60 min at room temperature. Then the supernatant was aspirated, and 
atrial myocytes were resuspended in fresh BSA solution. Myocytes were plated 
on laminin-coated glass coverslips, and incubated at 37°C with 5% CO2. The 
experimental procedure for isolating rabbit cardiac myocytes was approved by 
Vanderbilt University Institutional Animal Care and Use Committee.  
 
Atrial myocyte culture and adenoviral transduction 
Three hours after termination of enzymatic digestion, myocytes were placed into 
culture media consisting of MEM supplemented with Hank’s salts, 2 mM L-
glutamine (Gibco-Invitrogen, Life Technologies, Grand Island, NY), insulin-
transferrin-selenium-X supplement (Gibco-Invitrogen, Life Technologies, Grand 
Island, NY), penicillin (50 units/ml), streptomycin (50 μg/ml), 1% bovine serum 
albumin, 5 µM blebbistatin at pH 7.4 (modified from Kabaeva, et al.52). Virus was 
added to the myocytes at a MOI of 2,000 immediately after plating in culture 
media. To express WT-IKs, adenoviruses Ad5-KCNQ1-DsRedMST and Ad5-
KCNE1-eGFP were used to co-infect myocytes, whereas S140G-IKs was 
generated by co-infecting myocytes with adenoviruses Ad5-S140G-DsRedMST 
and Ad5-KCNE1-eGFP. Infected myocytes were cultured at 37°C in 5% CO2 and 
used for electrophysiology experiments 48-72 hours post-isolation. The efficiency 
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of dual transduction of healthy-appearing (striated, rod-shaped) myocytes was 
approximately 15-20%.  
 
Voltage clamp recording 
Potassium currents were recorded from CHO cells using the whole-cell 
configuration of the patch clamp technique.55 In dual transfection experiments 
examining channels composed of KCNE1 with just one KCNQ1 allele, only cells 
exhibiting yellow fluorescence (co-expression of dsRed-MST and eGFP) were 
studied. In triple transfection experiments designed to examine heteromeric 
channels composed of KCNE1 with both WT and mutant KCNQ1 subunits, 
yellow fluorescent cells with at least 3 adhered anti-CD8 Dynabeads® (Life 
Technologies, Grand Island, NY) were studied. The extracellular solution 
contained in mM: 132 NaCl, 4.8 KCl, 1.2 MgCl2, 1 CaCl2, 5 glucose, and 10 
HEPES, pH 7.4. In experiments with drug application, bath solution containing 
vehicle (<0.01% dimethyl sulfoxide) or HMR-1556 (1 nM - 2 μM) was applied by 
pencil perfusion using the Automate Valve-link perfusion system. HMR-1556 
((3R,4S)-(+)-N-[-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)chroman-4-yl]-N-
methyl-ethanesulfon-amide) was synthesized by the Vanderbilt Institute of 
Chemical Biology Synthesis Core using a published method.71 The standard 
intracellular solution contained in mM: 110 potassium aspartate, 1 CaCl2, 10 
HEPES, 11 EGTA, 1 MgCl2, and 5 K2ATP, pH 7.35. Pipette solution was diluted 
5-10% to prevent activation of swelling-activated currents. Patch pipettes were 
pulled from thick wall borosilicate glass (World Precision Instruments, Inc.) with a 
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multistage P-97 Flaming-Brown micropipette puller (Sutter Instrument Co., 
Novato, CA) and heat-polished with a Micro Forge MF 830 (Narashige 
International USA, Inc., East Meadow, NY). After heat polishing, the resistance of 
the patch pipettes was 2-4 megaohms in the standard solutions. A 2% agar 
bridge with composition similar to the control bath solution was used as a 
reference electrode. Unless otherwise stated, all chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO). 
 
Whole-cell currents were recorded at room temperature (20–23°C) using an 
Axopatch 200B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Test 
pulses were generated using Clampex 8.1 (MDS Analytical Technologies), and 
whole-cell currents were acquired at 5 kHz and filtered at 1 kHz. The access 
resistance and apparent membrane capacitance were estimated as described 
previously.56 Whole-cell currents were not leak subtracted. Junction potentials 
were zeroed with the filled pipette in the bath solution. All recordings were started 
4 min after achieving a whole cell patch. For concentration-response 
experiments, a single 2 s pulse to +40mV from a holding potential of −80 mV 
followed by a 1 s voltage step to −30mV was repeated every 10 s. Following 30 s 
of stable current levels, HMR-1556 was applied until 1 min of steady-state 
current was observed. For activation protocols, whole-cell currents were 
measured during a series of 2 s voltage steps from a holding potential of −80 mV 
to test potentials ranging from −80 to +60 mV (in 10 mV increments) followed by 
a 1 s step to −30 mV to record tail currents with a 20 s interpulse duration. For 
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current accumulation experiments, a single 2 s pulse to +40 mV followed by a 1 s 
step to −30mV was repeated for 1 minute with a 1 s interpulse duration.  
 
Voltage clamp data analysis 
Data were collected for each experimental condition from at least three separate 
transfections and analyzed using a combination of Clampfit (MDS Analytical 
Technologies), OriginPro 7 (OriginLab Corp., Northhampton, MA), and SigmaPlot 
2000 (Systat Software, Inc., Chicago, IL). To determine the kinetics of onset of 
and recovery from inhibition, fractional current remaining over time after 1 µM 
HMR-1556 application or after wash with bath solution was fitted with a 
monoexponential function (         
 
 
         ) where t indicates time,  is a 
time constant, A is an amplitude term and C is the fraction of unblocked current. 
The IC50 for inhibition of WT-IKs was determined by fitting the percent inhibition 
from 1 nM to 2 µM HMR-1556 with                                     
   for monophasic fits where Imin is the minimal current inhibition, Imax is the 
maximal current inhibition, IC50 is the concentration producing half maximal 
inhibition, x is log of concentration, and k is the Hill slope factor. For biphasic fits 
required for S140G-IKs, V141M-IKs and HET-IKs, we used               
                                                         where ImaxA 
and ImaxB are the maximal current inhibition for the high and the low affinity 
states, respectively, IC50A and IC50B are the concentrations that produce half 
maximal inhibition of the high or low affinity states, respectively, kA and kB are 
the Hill slope factors for the high and low affinity states, respectively. 
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Instantaneous current was measured 100 ms following a voltage step and 
steady-state current was measured at 1900 ms. Current density was obtained by 
normalizing current level to cell capacitance. Voltage dependence of activation 
was determined by plotting normalized peak tail current versus voltage, then 
fitting curves with a Boltzmann function to determine the voltage for half-maximal 
activation (V½) and the slope factor (k). Deactivation time constants were 
determined by fitting tail current decay with the monoexponential function shown 
above. 
 
Differences between two groups were assessed using unpaired Student's t test. 
One-way ANOVA followed by a Tukey post hoc test was performed when 
comparing more than two groups. Statistical tests were performed using 
SigmaStat 2.03 (Systat Software, Inc., Chicago, IL).  
 
Current clamp recording 
Action potentials were elicited from atrial myocytes using the whole-cell 
configuration of the patch clamp technique.55 Yellow, striated atrial myocytes 
were used for patch clamp experiments using previously described solutions.58 
The extracellular solution contained in mM: 140 NaCl, 5.4 KCl, 1 MgCl2, 1 CaCl2, 
7.5 glucose, 0.33 NaH2PO4, and 5 HEPES, pH 7.4. The intracellular solution 
contained in mM: 120 KCl, 10.25 NaCl, 5 MgCl2, 0.36 CaCl2, 5 HEPES, 5 EGTA, 
5 creatine phosphate (Tris), 5 glucose, and 5 K2ATP, pH 7.2. For drug 
application, bath solution containing vehicle (<0.01% dimethyl sulfoxide) or HMR-
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1556 (1 μM) was applied by pencil perfusion using the Automate Valve-link 
perfusion system. Patch pipettes were pulled from thick wall borosilicate glass 
(World Precision Instruments, Inc., Sarasota, FL) with a multistage P-97 Flaming-
Brown micropipette puller (Sutter Instrument Co., Novato, CA) and heat-polished 
with a Micro Forge MF 830 (Narashige International USA, Inc., East Meadow, 
NY). After heat polishing, the resistance of the patch pipettes was 1.5-2.5 
megaohms in the above solutions. A 2% agar bridge with composition similar to 
the control bath solution was used as a reference electrode.  
 
Action potentials were elicited at room temperature (20–23°C) using an Axopatch 
700B amplifier (MDS Analytical Technologies, Sunnyvale, CA). Pulses were 
generated using Clampex 9.1 (MDS Analytical Technologies), and action 
potentials were acquired at 10 kHz. No current was injected to maintain resting 
membrane potentials. To elicit action potentials, a stimulus threshold was 
determined for each myocyte, using a protocol of 0.1 nA steps of 3-4 ms 
duration. For experiments, 1.25 times stimulus threshold was used. Action 
potentials were elicited at 0.1 Hz for 5 min initially to achieve equilibration, and 
then at 1 Hz for experiments. HMR-1556 was applied after steady state action 
potential duration (APD) was achieved.  
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Current clamp data analysis 
Data were collected for each experimental condition from at least three separate 
myocyte isolations and analyzed using a combination of Clampfit 9.1 (MDS 
Analytical Technologies) and Excel 2010 (Microsoft). Data were transferred from 
Clampfit to Excel with each 1 Hz recording period contained in a separate file. A 
Visual Basic for Applications (VBA) program in Excel was written to read each file 
and to determine the resting membrane potential and atrial action potential 
duration at 90% (APD90) for each recorded action potential. The resting 
membrane potential (RMP) in mV was defined as the average value observed 10 
ms prior to the stimulus. APD90 was defined as time from the action potential 
overshoot to the return to 90% RMP. The overshoot was defined as the highest 
value after the current stimulus. All parameters determined were placed in a new 
Excel file organized by recording file name and trace number. To assess 
accuracy, parameters for randomly selected action potentials in each recording 
were verified manually using Clampfit. For each experimental condition, the 
parameters were averaged for the last 10 recorded action potentials. Differences 
between two groups were assessed using unpaired Student's t test. Statistical 
tests were performed using SigmaStat 2.03 (Systat Software, Inc.).  
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Results 
 
S140G-IKs exhibits enhanced sensitivity to HMR-1556 
We tested whether heterologously expressed IKs channel complexes consisting 
of either wildtype (WT) or mutant (S140G) KCNQ1 subunits in combination with 
the auxiliary subunit KCNE1 are inhibited by HMR-1556. Whole-cell recordings of 
CHO cells transfected with S140G and KCNE1 (S140G-IKs) demonstrated nearly 
instantaneous activation of outward current in contrast to the slowly activating 
current observed in cells expressing WT-IKs (Figure 47 A, B). Because KCNQ1-
S140G mutation-positive subjects were reported to be heterozygous in familial 
AF and because WT and mutant KCNQ1 subunits can co-assemble in 
heteromeric channels, we examined channel complexes consisting of both WT 
and mutant subunits co-expressed with KCNE1 (HET-IKs), which exhibited larger 
amplitudes with a large fraction of instantaneous current (Figure 47 C). 
Superfusion of 1 µM HMR-1556 completely and rapidly inhibited all channel 
complexes activated by low frequency pulsing (10 s interpulse duration) to +40 
mV (Figure 47 D-F). However, inhibition of S140G-IKs and HET-IKs was more 
pronounced than WT-IKs at lower concentrations. 
  
138 
 
 
  
F
ig
u
re
 4
7
. 
S
1
4
0
G
-I
K
s
 a
n
d
 H
E
T
-I
K
s
 e
x
h
ib
it
 e
n
h
a
n
c
e
d
 s
e
n
s
it
iv
it
y
 t
o
 H
M
R
-1
5
5
6
. 
A
, 
B
 a
n
d
 C
, 
R
e
p
re
s
e
n
ta
ti
v
e
 c
u
rr
e
n
t 
re
c
o
rd
in
g
s
 f
ro
m
 c
e
lls
 e
x
p
re
s
s
in
g
 W
T
-I
K
s
 (
A
),
 S
1
4
0
G
-I
K
s
 (
B
),
 o
r 
H
E
T
-I
K
s
 (
C
).
 R
e
c
o
rd
in
g
s
 i
llu
s
tr
a
te
d
 i
n
 A
, 
B
 a
n
d
 C
 
w
e
re
 
o
b
ta
in
e
d
 
u
s
in
g
 
th
e
 
a
c
ti
v
a
ti
o
n
 
p
ro
to
c
o
l 
d
e
s
c
ri
b
e
d
 
in
 
th
e
 M
e
th
o
d
s
. 
D
, 
E
, 
a
n
d
 
F
, 
A
v
e
ra
g
e
 c
u
rr
e
n
t 
d
e
n
s
it
ie
s
 
(c
u
rr
e
n
t 
n
o
rm
a
liz
e
d
 t
o
 c
e
ll 
c
a
p
a
c
it
a
n
c
e
) 
e
lic
it
e
d
 b
y
 a
 2
 s
 v
o
lt
a
g
e
 s
te
p
 t
o
 +
4
0
 m
V
 f
o
llo
w
e
d
 b
y
 a
 1
0
 s
 i
n
te
rp
u
ls
e
 d
u
ri
n
g
 
a
p
p
lic
a
ti
o
n
 o
f 
v
e
h
ic
le
 o
r 
v
a
ri
o
u
s
 c
o
n
c
e
n
tr
a
ti
o
n
 o
f 
H
M
R
-1
5
5
6
 f
ro
m
 c
e
lls
 e
x
p
re
s
s
in
g
 W
T
-I
K
s
 (
D
),
 S
1
4
0
G
-I
K
s
 (
E
),
 o
r 
H
E
T
-I
K
s
 (
F
).
 C
u
rr
e
n
t 
d
e
n
s
it
y
 t
ra
c
e
s
 i
n
 D
, 
E
, 
a
n
d
 F
 a
re
 a
v
e
ra
g
e
s
 f
ro
m
 9
-1
1
 c
e
lls
. 
139 
 
We assessed concentration-response relationships for WT-IKs, S140G-IKs, and 
HET-IKs to determine whether the channel complexes have different affinities for 
HMR-1556 (Figure 48). Cells expressing WT-IKs exhibited a concentration-
response curve that was fit by the Hill equation yielding an IC50 of 214nM and Hill 
coefficient of 1.2. By contrast, S140G-IKs exhibited a complex concentration-
response that suggested two affinity states. The IC50 of the high affinity state was 
3.7nM, whereas the lower affinity state had an IC50 of 97.7nM. Both states were 
significantly different from the IC50 for WT-IKs (p<0.001). Hill coefficients for the 
high (2.2) and low (2.5) affinity states on S140G-IKs suggested positive 
cooperative binding of the drug. The gating kinetics of the current sensitive to 
30nM HMR-1556, a concentration near the crux between the two affinity states 
on the concentration-response curve, was not overtly different than drug-
insensitive current (Figure 49) suggesting that the two affinity states do not 
emerge from distinct populations of channels. The HET-IKs complex 
demonstrated an intermediate pharmacologic phenotype with a complex 
concentration-response curve. The high affinity state had an IC50 of 5.1nM (Hill 
coefficient 1.7) whereas the low affinity state IC50 was 240nM (Hill coefficient 
2.4). 
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Figure 48. HMR-1556 concentration-response curves for WT-IKs, S140G-IKs, and HET-
IKs. HMR-1556 (1 nM - 2 µM) applied to WT-IKs (○), S140G-IKs (Δ), and HET-IKs (●). Solid 
lines represents fits of the averaged data to either monophasic (WT-IKs) or biphasic 
(S140G-IKs and HET-IKs) Hill function (see Supplemental Material). IC50 values and Hill 
coefficients are provided in the text.  
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Figure 49. HMR-1556 sensitive and insensitive current for S140G-IKs. Average current 
densities for S140G-IKs recorded in the absence (black trace) or presence (red trace) of 
30 nM HMR-1556. HMR-1556 sensitive current (blue trace) was determined by digitally 
subtracting the residual current (red trace) from the total current (black trace).  
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There were also substantial differences in the kinetics of HMR-1556 inhibition. 
Specifically, on- and off-rates observed for suppression of S140G-IKs were 
significantly slower than WT-IKs (Figure 50 A, B). The dramatically slower off-rate 
for S140G-IKs suggested a stronger interaction between HMR-1556 and the 
channel consistent with our finding that the mutant subunit confers an enhanced 
affinity for the drug. The intermediate phenotype of HET-IKs exhibited an on-rate 
comparable to WT-IKs but a significantly slower off-rate that was more similar to 
S140G-IKs. This enhanced sensitivity suggested an opportunity to selectively 
suppress the mutant current with minimal effects on WT-IKs.  
 
V141M-IKs exhibits enhanced sensitivity to HMR-1556 
We also determined the pharmacologic effects of HMR-1556 on another 
previously reported gain-of-function KCNQ1 mutation, V141M, associated with 
early onset AF.15 V141M-IKs exhibited enhanced sensitivity to HMR-1556 and a 
complex IC50 binding curve with values similar to S140G-IKs (Figure 51). The off-
rate was significantly slower than WT-IKs (Figure 50 C, D). These data 
demonstrate that increased HMR-1556 sensitivity was not specific to S140G-IKs. 
All further experiments were conducted with S140G-IKs as a prototypic familial AF 
mutation.  
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Figure 50. Kinetics of inhibition by HMR-1556. A, Onset of inhibition elicited by 
application of 1 µM HMR-1556 for WT-IKs (○), S140G-IKs (Δ), and HET-IKs (●) illustrated 
for representative cells. On rates: WT-IKs, 0.10 ± 0.01 sec
-1; S140G-IKs, 0.032 ± 0.005 
sec-1; HET-IKs, 0.12 ± 0.01 sec
-1, p<0.001 for S140G-IKs compared to HET-IKs and WT-IKs; 
B, Recovery from inhibition by 1 µM HMR-1556 for WT-IKs (○), S140G-IKs (Δ) and HET-
IKs (●) illustrated for representative cells. Off rates: WT-IKs, 0.018 ± 0.001 sec
-1; S140G-
IKs, 0.0020 ± 0.0001 sec
-1; HET-IKs, 0.0048 ± 0.0009 sec
-1; p<0.001 for HET-IKs and 
S140G-IKs compared to WT-IKs; C, Onset of inhibition elicited by application of 1 µM 
HMR-1556 for V141M-IKs (▲) illustrated for representative cells. WT-IKs (○) shown for 
reference. On rate: V141M-IKs, 0.09 ± 0.02 sec
-1 (not statistically significant versus WT-
IKs). D, Recovery from inhibition by 1 µM HMR-1556 for V141M-IKs (▲) illustrated for 
representative cells with WT-IKs (○) shown for reference. Off rate: V141M-IKs, 0.004 ± 
0.002 sec-1 (p<0.001 versus WT-IKs). In A-D, the data represent the current amplitude 
recorded at 1990 ms after a test pulse to +40 mV and normalized to current recorded at 
the initial pulse (n = 4-7).  
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Figure 51. V141M-IKs exhibits enhanced sensitivity to HMR-1556. A, Representative 
current densities (current normalized to cell capacitance) recorded from cells expressing 
WT-IKs that were elicited by a 2 s voltage step to +40 mV followed by a 10 s interpulse 
during application of vehicle or various concentration of HMR-1556. B, HMR-1556 
concentration-response curves for V141M-IKs (▲) and WT-IKs (○). Solid lines represents 
fits of the averaged data (9-11 cells) to a biphasic Hill function (see Supplemental 
Material). For V141M-IKs, the high affinity state had an IC50 of 0.72 nM and Hill coefficient 
of 0.6; the low affinity state had an IC50 of 204 nM and Hill coefficient of 1.7.  
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Properties of heteromeric S140G-IKs and WT-IKs 
We elucidated the functional properties of HET-IKs. Compared to WT-IKs, cells 
expressing HET-IKs exhibited larger amplitudes with a large fraction of 
instantaneous current between 80 and 20 mV (Figure 52). At more positive 
voltage steps (20 to +60 mV), HET-IKs exhibits both time-dependent and 
constitutive activation with significantly greater current density than WT-IKs 
(Figure 52). The voltage dependence of activation was shifted significantly in the 
hyperpolarized direction for HET-IKs (V1/2: HET-IKs, 1.4±8.1 mV; WT-IKs, 30.1±9.3 
mV; p<0.001) without any difference in slope factor (Figure 52). The time course 
of deactivation was extremely slow for HET-IKs as compared to WT-IKs (Figure 
52).  
 
During repetitive depolarization to +40 mV with a short recovery period, both WT-
IKs and HET-IKs exhibited a use-dependent accumulation of instantaneous and 
steady-state current over time, but HET-IKs current density was significantly 
greater than WT-IKs at each successive pulse (Figure 53). The ratio of 
instantaneous to steady-state current at the end of this protocol, a proxy for the 
degree of constitutive activation, was much greater for HET-IKs (84±3%) than 
WT-IKs (38±4%; p<0.001). These findings illustrate the dynamic nature of IKs and 
further emphasize the biophysical consequences of the gain-of-function mutation, 
KCNQ1-S140G. 
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Figure 52. Functional properties of Het-IKs. A, Voltage dependence of instantaneous 
current density recorded 100 ms after onset of the voltage step for WT-IKs (○, n = 19) 
and HET-IKs (●, n = 19). Differences were significant at the p<0.001 level for voltages 
between 60 and +60 mV. B, Voltage dependence of steady-state current density 
recorded 1990 ms after onset of the voltage step for WT-IKs (○) and HET-IKs (●). Current 
densities are significantly different (p<0.02) between WT-IKs and HET-IKs at all voltages 
except −70 mV (reversal potential). C, Voltage dependence of activation for WT-IKs (○, n 
= 16) and HET-IKs (●, n = 13). Solid lines represent average of Boltzmann fits to data 
from individual cells. Values for slope factor were not different between WT-IKs (16.9 ± 
0.6) and HET-IKs (20.9 ± 3). Values for V1/2 are provided in the text. D, Deactivation 
kinetics illustrated for WT-IKs (n = 9) and HET-IKs (n = 11). Tail currents were elicited by a 
2 s test pulse to +40 mV from a holding potential of −80 mV followed by sequential 2 s 
test pulses from −40 mV to −100 mV in 10 mV increments. At −100mV, HET-IKs has a 
significantly slower deactivation rate than WT-IKs (1.22e-3 ± 0.11e-3, vs. 2.28e-3 ± 
0.25e-3; p<0.02). 
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Figure 53. HET-IKs exhibits use-dependent current accumulation. A and B, 
Representative current recordings during repetitive pulsing from cells expressing WT-IKs 
(A) or HET-IKs (B). For A and B, cells were repetitively depolarized to +40 mV for 2 s and 
then to 30 mV for 1 s followed by a 1 s interpulse interval at the holding potential. The 
first pulse is indicated by the arrow. C, Use dependence of instantaneous current density 
for cells expressing WT-IKs (○, n = 13) and HET-IKs (●, n = 14). Differences were 
significant at the p<0.001 level for all pulses. D, Use dependence of steady-state current 
density for WT-IKs (○) and HET-IKs (●) expressing cells. Differences were significant at 
the p<0.03 level for all pulses. 
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Selective inhibition of HET-IKs with HMR-1556 
Given the enhanced sensitivity of S140G-IKs to HMR-1556, we hypothesized that 
HET-IKs could be selectively suppressed by using a concentration HMR-1556 that 
predominantly inhibits the high affinity state. To test this hypothesis, we applied 
20nM HMR-1556 or vehicle to heterologously expressed channels and assessed 
the effects of drug on gating kinetics and current amplitudes. 
 
Vehicle had no effects on the behavior of WT-IKs and HET-IKs (Figure 54 A,B). 
Further, 20nM HMR-1556 had no appreciable effect on current levels or gating 
behavior of WT-IKs (Figure 54 C), but the drug exerted notable effects on HET-IKs 
including suppression of both instantaneous and steady-state current amplitude 
and attenuation of use-dependent current accumulation (Figure 54 D). The 
effects of 20nM HMR-1556 on WT-IKs and HET-IKs are quantified in Figure 55. 
Importantly, 20nM HMR-1556 did not inhibit WT-IKs, but did reduce the amplitude 
of HET-IKs to levels that were not significantly different from WT-IKs. Additionally, 
the ratio of instantaneous to steady-state current for HET-IKs was also modified 
by the drug to a value that was not significantly different from WT-IKs (Figure 55). 
These findings demonstrated the selective suppression of HET-IKs and the 
normalization of this mutant current to WT-IKs levels.  
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Figure 55. Selective inhibition of HET-IKs by HMR-1556. A, Voltage dependence of instantaneous 
current density for vehicle-treated WT-IKs (○, n = 10), vehicle-treated HET-IKs (●, n = 11), HMR-1556 
(20 nM) treated WT-IKs (□, n = 10), and HMR-1556 (20 nM) treated HET-IKs (■, n = 9). Differences 
between vehicle-treated HET-IKs and other groups were significant at the p<0.001 level for voltages 
between 20 and +60 mV. B, Voltage dependence of steady-state current density for vehicle or HEM-
1556 treated WT-IKs or HET-IKs (symbols defined in A). Differences between vehicle-treated HET-IKs 
and other groups were significant at the p<0.02 level for voltages between 40 and +60 mV. C, Use 
dependence of instantaneous current density for vehicle or HEM-1556 treated WT-IKs or HET-IKs 
(symbols defined in A). Differences between vehicle-treated HET-IKs and other groups were significant 
at the p<0.001 level at all tested potentials. D, Use dependence of steady-state current density for 
vehicle or HEM-1556 treated WT-IKs or HET-IKs (symbols defined in A). Differences between vehicle-
treated HET-IKs and other groups were significant at the p<0.02 level at all tested potentials. In A-D, 
there were no differences among vehicle-treated WT-IKs, HMR-1556 treated WT-IKs, and HMR-1556 
treated HET-IKs. E, Ratios of instantaneous current density to steady-state current density. Differences 
between vehicle-treated WT-IKs (open black bar) or HET-IKs (solid black bar) was significant at 
p<0.001, whereas there was no significant difference between HMR-1556 treated WT-IKs (open red 
bar) and HET-IKs (solid red bar).   
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HMR-1556 mitigates S140G-IKs-induced atrial action potential duration 
shortening 
We examined the effects of HMR-1556 on action potentials in cultured adult 
rabbit left atrial myocytes expressing WT-IKs or S140G-IKs channel complexes. 
Action potentials were elicited at 1 Hz during whole-cell current clamp recording 
of adenovirus transduced atrial myocytes. Expression of S140G-IKs in left atrial 
myocytes hyperpolarized the resting membrane potential and significantly 
reduced 90% action potential duration (APD90) compared to WT-IKs expression 
(APD90: WT-IKs, 177.4 ± 21.0 msec; S140G-IKs, 68.9 ± 19.2 msec; p<0.001) 
(Figure 56 A). Application of 1µM HMR-1556 did not alter APD90 of WT-IKs 
expressing myocytes (185.2 ± 27.3 msec, p>0.4), whereas application of 1µM 
HMR-1556 significantly lengthened APD90 of S140G-IKs expressing myocytes 
(117.1 ± 12.7 msec, p<0.04) (Figure 56 B). These findings illustrate that HMR-
1556 can selectively suppress S140G-IKs effects on atrial action potential 
duration without altering action potentials in myocytes expressing WT-IKs.  
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Figure 56. HMR-1556 mitigates atrial action potential shortening by S140G-IKs. 
Representative averages of 10 sequential action potentials from cultured rabbit left atrial 
myocytes expressing either WT-IKs (black line, n=6) or S140G-IKs (blue line, n=6). A, 
Action potentials elicited after application of vehicle. B, Action potentials elicited after 
application of 1 µM HMR-1556. APD90 values are provided in the text. 
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Discussion 
The discovery of mutations in familial AF illustrated the contribution of specific 
genetic factors to AF susceptibility and suggested molecular mechanisms for 
some heritable forms of this common arrhythmia. For gain-of-function KCNQ1 
mutations in particular, we sought to exploit this knowledge to explore a potential 
targeted therapy. Specifically, we hypothesized that KCNQ1 mutations 
predisposing to AF encode potassium channels with distinct pharmacological 
properties that could render them susceptible to selective inhibition. Genotype-
specific therapies for inherited arrhythmia syndromes such as congenital long-QT 
syndrome and catecholaminergic polymorphic ventricular tachycardia are 
emerging.76, 77 Further, a precedent for mutation-specific pharmacology of a rare, 
inherited disorder was established by the approval of ivacaftor for treatment of 
cystic fibrosis caused by CFTR-G551D.78  
 
In this study, we investigated the utility of the selective and high affinity IKs 
blocker HMR-1556 to inhibit gain-of-function KCNQ1 mutations S140G and 
V141M. Chromanol 293B was the first identified selective IKs blocker, which 
exerts its effect at low micromolar concentrations.79 The chromanol derivative 
HMR-1556 was developed to increase potency and improve the selectivity of IKs 
inhibition.75 This derivative was initially demonstrated to have an IC50 of 120 nM 
against IKs expressed in Xenopus oocytes with little effect on other recombinant 
potassium channels at 10 µM consistent with a high level of specificity.75 In 
isolated canine ventricular myocytes, HMR-1556 inhibits IKs with a nanomolar 
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IC50 whereas inhibition of other ionic currents (e.g., IKr, IK1, Ito, ICa,L) required much 
higher concentrations.80  
 
Consistent with our hypothesis, we observed that S140G-IKs exhibits enhanced 
sensitivity to HMR-1556. This enhancement was correlated with the emergence 
of an additional high affinity state, which was also observed with V141M-IKs. 
Importantly, using a concentration that predominantly inhibits the high affinity 
state, we demonstrated that HMR-1556 effectively suppressed HET-IKs amplitude 
to a level that was not significantly different from WT-IKs. Further, this drug 
concentration attenuated the use-dependent accumulation of HET-IKs that occurs 
during repetitive pulsing. Significantly, we demonstrated that HMR-1556 can 
mitigate the S140G-IKs induced APD shortening in cultured adult rabbit atrial 
myocytes without affecting action potentials in myocytes expressing WT-IKs. 
These findings offer evidence supporting the potential for genotype-specific 
therapy of familial AF.  
 
The potential utility of HMR-1556 or a similarly acting drug in the setting of 
familial AF should be considered in the context of the liabilities of inhibiting IKs in 
tissues other than atria. Reduction of IKs in ventricular muscle carries the risk of 
reduced repolarization reserve and predisposition to reentrant arrhythmia as in 
type 1 congenital long-QT syndrome. In anesthetized dogs receiving continuous 
intravenous infusions of HMR-1556, there was significant QTc prolongation and 
reproducible triggering of torsades de points with an isoproterenol bolus.81 
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Prolongation of QTc during HMR-1556 exposure is accentuated in dogs by co-
administration of the IKr blocker dofetilide.
82 In Langendorff-perfused rabbit 
hearts, HMR-1556 alone was not sufficient to prolong monophasic action 
potential duration (APD) but co-administration of either dofetilide alone or 
dofetilide with veratridine caused significant lengthening of APD.83, 84 These 
reports emphasize the potential proarrhythmic effects of high concentration 
HMR-1556 or of concurrent IKs and IKr inhibition. Fortunately, our data indicate 
that selective inhibition of S140G-IKs can be achieved at HMR-1556 
concentrations that do not suppress WT-IKs. 
 
Ototoxicity is another potential concern with HMR-1556. Because IKs expressed 
in the stria vascularis of inner ear is important in the generation of the K+ rich 
cochlear endolymph, disruption of IKs has the potential to impair hearing as 
observed in autosomal recessive Jervell-Lange-Nielson syndrome associated 
with KCNQ1 or KCNE1 mutations.85-87 Indeed, high concentrations of HMR-1556 
exert a reversible ototoxicity in cats.88 Again, our data suggest that there is a 
potential concentration range that may be free of inner ear adverse effects.  
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In summary, the AF-associated mutations KCNQ1-S140G and KCNQ1-V141M 
confer enhanced sensitivity to HMR-1556 in the context of the IKs channel 
complex. At a concentration that predominantly suppresses current by interacting 
with a novel high affinity state expressed by the S140G mutant, HMR-1556 
normalized current amplitudes to levels that are not significantly different from 
WT-IKs, and attenuated the use-dependent accumulation of current. In cultured 
adult rabbit atrial myocytes, HMR-1556 mitigated the shortened APD induced by 
S140G-IKs expression. Our demonstration of selective targeting of this gain-of-
function mutation provides a potential proof-of-principal for genotype-specific 
treatment of familial AF. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults. 
With a rising incidence in the aging population and association with significant 
morbidity and increased mortality, AF is a major public health burden. The 
discovery of mutations in familial AF illustrated the contribution of specific genetic 
factors to AF susceptibility and suggested molecular mechanisms for some 
heritable forms of this common arrhythmia. This dissertation focused on the first 
identified causative familial AF mutation (S140G) in the voltage gated potassium 
channel gene KCNQ1. Together with the auxiliary subunit KCNE1, KCNQ1 forms 
the slow component of the delayed rectifier potassium current, IKs. In the heart, 
IKs is critical to myocardial repolarization and action potential shortening in 
response to β adrenergic stimulation. We used S140G-IKs to explore AF 
mechanisms and therapeutic opportunities in familial AF. 
 
Because transgenic S140G mouse models were inadequate for reproducing an 
AF-prone substrate, we first developed methods for high yield isolation, extended 
culture, and transfection of adult atrial myocytes suitable for electrophysiological 
experiments from more human-like cardiac model organisms, guinea pigs and 
rabbits. While guinea pig atrial and ventricular myocytes could be isolated 
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simultaneous, multi-chamber isolation of adult rabbit myocytes required more 
extensive modifications to the traditional Langendorf methods. Using a novel 
serial sampling technique, we were able to achieve reproducible high yields of 
both ventricular and atrial myocytes. After ventricular digestion, sequential 
recannulation and digestion of the left and right atria was critical for individual 
myocyte isolation. Yields of calcium tolerant cardiomyocytes were further 
enriched by gravity pelleting between wash steps, plating on laminin-coated 
coverslips, and at least a 2 h recovery time before exposure to physiological 
levels of calcium in culture media. The culture of adult cardiac myocytes with 
preserved morphology for 5 days was optimized through the use of laminin as an 
extracellular matrix to promote cell adherence, the identification of MEM as a 
base for culture media, the addition of pH buffering capacity, and the use of a low 
concentration of the E/C-uncoupler, blebbistatin. For the transfection of adult 
cardiac myocytes, biolistics and viral methods were successful. Adenovirus-
mediated transduction proved most efficient in guinea pig and rabbit myocyte 
preparations with high titers and robust expression of transgenes. 
Electrophysiology confirmed the utility of these isolated cultured myocytes for 
future experiments.  
 
Using this rabbit adult atrial myocyte model system, we advanced the insights 
garnered from characterization of monogenic AF mutations in heterologous 
systems and mathematical model by investigating the impact of S140G-IKs 
expression in native atrial myocytes. We presented evidence that under our 
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recording conditions IKs is not endogenously expressed in rabbit atrial myocytes. 
In addition, to exogenously express IKs in rabbit atrial myocytes, a modified 
adenoviral promoter must be used to generate the potassium channel virus and a 
very high MOI is necessary to generate expression. Further, we created a 
program to facilitate the high throughput analysis of action potentials. In S140G-
IKs expressing myocytes, we revealed evidence of triggered activity at low 
frequency stimulation and a shorter action potential duration at higher frequency 
with hyperpolarized resting membrane potential compared to WT-IKs expressing 
myocytes. Overall, we illustrated effects of the FAF-associated mutation S140G-
IKs in a native albeit cultured adult atrial myocyte supporting the hypothesis that a 
shortened APD likely underlies substrate susceptibility. 
 
Springing from these observations, we sought to explore potential targeted 
therapeutic opportunities to ameliorate the physiological consequences of a 
KCNQ1 gain-of-function mutation. Specifically, we hypothesized that KCNQ1 
mutations predisposing to AF encode potassium channels with distinct 
pharmacological properties that could render them susceptible to selective 
inhibition. Consistent with our hypothesis, we observed that S140G-IKs exhibits 
enhanced sensitivity to the IKs-selective blocker, HMR-1556. This enhancement 
was correlated with the emergence of an additional high affinity state, which was 
also observed with V141M-IKs, a neighboring gain-of-function AF-associated 
mutation. Because KCNQ1-S140G mutation-positive subjects were reported to 
be heterozygous in familial AF and because WT and mutant KCNQ1 subunits 
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can co-assemble in heteromeric channels, we examined channel complexes 
consisting of both WT and mutant subunits co-expressed with KCNE1 (HET-IKs), 
which exhibited larger amplitudes with a large fraction of instantaneous current. 
Importantly, using a concentration that predominantly inhibits the high affinity 
state, we demonstrated that HMR-1556 effectively suppressed HET-IKs amplitude 
to a level that was not significantly different from WT-IKs. Further, this drug 
concentration attenuated the use-dependent accumulation of HET-IKs that occurs 
during repetitive pulsing. Significantly, we demonstrated that HMR-1556 can 
mitigate the S140G-IKs induced APD shortening in cultured adult rabbit atrial 
myocytes without affecting action potentials in myocytes expressing WT-IKs. 
These findings offer evidence supporting the potential for genotype-specific 
therapy of familial AF.  
 
Future directions 
The work discussed in this dissertation provides multiple avenues for the further 
scrutiny of AF substrate susceptibility and the possible therapeutic value of HMR-
1556. The establishment of the adult rabbit atrial myocyte model system with 
exogenous ion channel expression enables further investigation into the genesis 
of FAF substrate susceptibility as related to S140G-IKs and other gain-of-function 
mutations in combination with other known acquired AF susceptibility factors. 
The intriguing increased sensitivity of S140G-IKs to HMR-1556 provokes 
questions about the biophysical determinants of HMR-1556 specificity to IKs. 
Further the increased sensitivity of V141M-IKs evokes a broader possible role for 
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HMR-1556 with additional KCNQ1 FAF mutations and encourages further 
consideration of HMR-1556 as a possible therapeutic. Each of these intriguing 
experimental possibilities will be reflected upon in turn.  
 
AF susceptibility in the cultured rabbit atrial myocyte model 
The model system developed for investigating S140G-IKs expression effect on 
rabbit atrial myocytes can be further used to determine the effects of acquired AF 
susceptibility factors, to explore the possible differential effects of other KCNQ1 
FAF-associated mutations on atrial APD, and to investigate the pleiotropy with 
LQTS observed in some patients. Further, a native atrial myocyte system can be 
exploited to dissect pharmacologically the effect of familial AF-associated KCNE 
mutations on the atrial action potential and atrial potassium currents.  
 
Effect of acquired AF factors on S140G-IKs expressing rabbit atrial myocytes 
Although we elucidated the effects of S140G-IKs on rabbit atrial myocytes, this 
effect alone is not enough for the clinical manifestation of AF as this arrhythmia 
does not present in childhood. Unknown are what factors acquired during life are 
needed for AF manifestation. How S140G-IKs genetic susceptibility interacts, 
potentially additively or synergistically, with known acquired AF susceptibility 
factors needs to be explored. Considered here are AF contributing factors of 
oxidative stress and electrical remodeling. 
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Oxidative stress has been implicated in the pathogenesis of AF by several 
studies and is an established factor that increases with aging.89 Oxidative stress 
also profoundly affects gating properties of ion channels.90 Yet the mechanism or 
mechanisms by which ROS could promote AF are not well understood. Although 
we determined that oxidative stress mimicked by application of tert-butyl 
hydroperoxide (t-BHP) does not directly potentiate the activity of S140G-IKs (data 
not shown), how oxidative stress alters native myocyte predisposition to AF and 
whether S140G-IKs exert additive or synergistic in this circumstance is unknown. 
Analysis of the current and action potential alterations in S140G-IKs expressing 
myocytes under acute or prolonged exposure to tBHP will provide insight into the 
effects of oxidative stress on this genetically-encoded AF risk factor.  
 
AF itself can induce substrate vulnerability through electrical remodeling induced 
by tachypacing. These changes include shortened APD, increased outward 
potassium current, DAD predisposition, and downregulation of calcium and 
sodium currents. Future studies can test the hypothesis that S140G-IKs affects 
atrial myocyte adaptation to conditions that promote electrical remodeling in a 
manner that potentiates the effects of these factors to produce an AF-prone 
cellular substrate. These myocyte studies could elucidate electrophysiological 
changes that occur in the context of electrically remodeled cells. During culture of 
S140G-IKs expressing rabbit atrial myocytes, the culture can be paced rapidly to 
induce remodeling. Recorded potassium currents and action potentials may help 
elucidate how S140G-IKs adapts to tachypacing compared to WT-IKs controls.  
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Anticipated results: These studies might reveal how S140G-IKs could work 
synergistically or additively to promote AF vulnerability in the context of oxidative 
stress or electrical remodeling. Given that we observed triggered activity in 
S140G-IKs at low frequency, this predisposition may be augmented with exposure 
to t-BHP and the threshold for triggered activity may be lower. Further high 
frequency stimulus of action potentials exacerbated the shortened APD induced 
by S140G-IKs. Because electrical remodeling shortens APD, this tachypacing in 
culture may have an additive effect on APD abbreviation and further augment 
potassium channel current. In the context of a electrical remodeled myocyte, the 
predisposition of S140G-IKs expressing myocytes to triggered activity likely may 
be enhanced. Together, these experiments could elucidate the interaction 
between genetic and acquired AF susceptibility factors. 
 
Effect of other familial AF-associated mutations in rabbit atrial myocytes 
With an established model system for expressing and analyzing the effects of 
S140G-IKs on rabbit atrial myocytes, this system can be used to further explore 
the effects of other atrial fibrillation associated mutations in a native atrial cardiac 
myocyte environment. The initial candidates would be the KCNQ1 mutations 
V141M, R231C, and R231H, which all have some constitutive activity in 
heterologous experiments. In addition, familial AF associated mutation, KCNQ1-
IAP54-56 demonstrates gain-of-function in current density but does not have a 
constitutively active component. Whether this mutation effects the rabbit atrial 
myocyte in a similar fashion to S140G-IKs would be intriguing. Adenovirus can be 
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created to express each of these mutations and used to transduce rabbit atrial 
myocytes. The potassium currents and the action potentials can be elicited 
through whole cell patch clamp and analyzed. In addition to response to 
increased stimulus frequency, the response to adrenergic stimulation such as 
isoproterenol could be revealing. 
 
Anticipated results: Expression of the other familial AF mutations could shorten 
rabbit atrial potential duration and augment potassium current density. However, 
we anticipate variability in the degree of shortening. Given the earliest AF onset 
was with V141M, we anticipate the shortest APD from myocytes expression 
V141M-IKs. Further, without constitutive activity component, we anticipate a 
smaller effect on APD with IAP-54-56-IKs and possibly less APD shortening in 
response to increased stimulation frequency. Further these myocytes may have 
differential sensitive to adrenergic stimulation that could augment their 
contribution to AF susceptibility. These experiments would reveal commonalities 
between gain-of-function KCNQ1 mutation and their contribution to AF 
susceptibility. A common mechanism between genetic causes of AF would 
provide a larger target for therapeutic intervention. 
 
Examine AF and LQT1-associated mutation pleiotropy in rabbit myocytes 
Although S140G-IKs was identified as the causative mutation in familial AF, many 
affected familial members also had a prolonged QT interval. Similarly, the related 
KCNQ1 mutation, R231C, was first associated with LQT1 and only recently has 
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been implicated in familial AF. This observed pleiotropy in individuals and 
between families provokes the hypothesis that these mutations have differential 
effects in atrial myocytes than in ventricular myocytes. Both S140G-IKs and 
R231C-IKs have a constitutively active component; yet R231C-IKs has been 
shown to have a decrease in current density. How these attributes may alter 
ventricular myocytes is not known. To address, this hypothesis adenovirus 
expressing either S140G-IKs or R231C-IKs can be used to transduce rabbit 
ventricular myocytes. The potassium current and action potential can be 
recorded.  
 
Anticipated results:. We anticipate a prolongation of APD in R231C-IKs 
expressing ventricular myocytes due to its decrease in current density. We 
predict a shortening in ventricular APD in S140G-IKs. Yet we anticipate altered or 
diminished responses to β-adrenergic stimulation which may promote APD 
prolongation characteristic of a prolonged QT interval, or increased triggered 
activity which may reflect altered calcium dynamics. These experiments would 
illustrate whether these mutations have differential effects on ventricular 
myocytes that might clarify the observed pleiotropy in AF and prolonged QT 
interval. 
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Impact of familial AF-associated KCNE mutations on rabbit atrial myocytes 
In addition to familial AF associated mutations in the pore-forming potassium 
channel KCNQ1, familial AF associated mutations in auxiliary single 
transmembrane KCNE subunits have also been reported: KCNE2-R27C,22 
KCNE2-X124N,23 and KCNE3-V17M.24 Initial heterologous experiments have 
illustrated that these mutation increase currents when co-expressed with 
KCNQ1. However, KCNEs are promiscuous and interact with multiple voltage-
gated potassium channels. How these interactions contribute to the cardiac 
action potential and how mutations might perturb these interactions are unknown. 
We hypothesize that these mutations would shorten overall APD though 
alternation of many different potassium currents. Adenoviral expression of these 
mutations or the respective wild-type KCNE in rabbit atrial myocytes and analysis 
of potassium currents and action potentials would address this hypothesis.  
 
Anticipated results: We predict that expression of these familial AF-associated 
mutations may shorten the atrial action potential and overall increase the 
potassium current in atrial myocytes. Application of specific potassium channel 
blockers would reveal the relative contribution of the KCNEs to specific channels 
expression. Given the known interactions of KCNE2 and KCNE3 with IKs, ITO, IKr, 
we predict that these experiments might demonstrate alteration to each current 
and augment our understanding of KCNEs in action potential determination. 
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Biophysics of HMR-1556 inhibition 
Beyond the experiment opportunities provided by cultured rabbit atrial myocyte 
model, the increased sensitivity of S140G-IKs and V141M-IKs to HMR-1556 
provokes some fundamental biophysical questions about the mechanism of 
HMR-1556 inhibition and of HMR-1556 to IKs. The importance of the abnormal 
gating properties of the mutant channels to HMR-1556 sensitivity and the 
complex binding curve of HMR-1556 inhibition of these mutants suggest further 
exploration. 
 
HMR-1556 inhibition requires KCNE1 coexpression with KCNQ1. Yet previous 
work demonstrated that point mutations in KCNE1 were unsuccessful in 
abolishing or diminishing IKs chromanol sensitivity
91 suggesting that KCNE1 acts 
allosterically to promote drug sensitivity. The additive sensitivity noted with 
S140G and V141M mutations, which notably require KCNE1 to reveal their gain-
of-function, is provocative. Our studies have demonstrated no enhanced 
sensitivity to HMR-1556 when S140G-Q1 is expressed without KCNE1 (data not 
shown) suggesting that the residue change itself is not sufficient. To address 
whether the abnormal channel gating properties conferred by these mutations is 
responsible for increased sensitivity, experiments can be conducted with 
channels having similar gating properties. In particular, the non-disease linked 
mutation, Q1-R237A, has a similar phenotype of ultraslow deactivation yet does 
not require KCNE1 co-expression.18 Moreover, R237 is predicted to interact with 
V141 and S140 in the open state. Experiments with R237A could determine if the 
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constitutively activity conferred by disruption of this residue interaction is 
sufficient for HMR-1556 sensitivity. Furthermore, the KCNE3 co-expression with 
KCNQ1 results in a similar increased current density and had a near 
instantaneous activation rate. Whether KCNQ1-KCNE3 complex has increased 
sensitivity would be intriguing and would further suggest that KCNQ1 with these 
gating properties promotes for HMR-1556 sensitivity. In addition to the potassium 
channel gating properties, the complex HMR-1556 inhibition curve of S140G-IKs 
and V141M-IKs suggests either a second binding affinity state or a second 
binding affinity site for HMR-1556. Previous work with chromanol 293B, 
structurally similar to HMR-1556, demonstrated a slight preferential open channel 
block mechanism. The binding site was predicted to be in the inner pore of 
vestibule containing the ion selectivity filter of Q1, but the open state alone did 
not enhance sensitivity.91, 92 We attempted to apply HMR-1556 to a closed 
S140G-IKs, but the degree of hyperpolarization and time (>4 mins) required to 
close the channel completely was not commensurate with CHO cell viability. 
Computational modeling of drug docking could provide insights into the 
differential blockade observed in mutant and wild-type channels. 
 
Anticipate results: Future work with R237A and KCNQ1-KCNE3 might reveal 
whether the gating dynamics of KCNQ1 are critical to enhanced sensitive of 
HMR-1556 or whether the disruption of the R231-V141/S140-E160 is important 
for increased sensitivity. Computational modeling and drug docking studies might 
help determine whether the mutations expose a second binding site or provide a 
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second affinity state for the drug to preferentially bind. These data could be used 
to design site-directed mutagenesis to further probe the nature of HMR-1556 
specific to IKs inhibition. 
 
HMR-1556 as a potential therapeutic agent 
The increased sensitivity of S140G-IKs and V141M-IKs to HMR-1556 compared to 
WT-IKs suggested a potential therapeutic opportunity, to inhibit these gain-of-
function mutations AF predisposing mutations without deleterious effects on the 
WT channel. Indeed in a heterologous system and in rabbit atrial myocytes, we 
demonstrated that HMR-1556 could mitigate the effect of S140G-IKs on 
potassium currents and action potential duration without WT channel blockade. 
These data suggest further exploration of HMR-1556 as a potential therapeutic 
agent for familial AF. Considering the similar increased sensitivity of V141M-IKs, 
whether other familial AF associated mutations had enhanced sensitivity to HMR-
1556 would expand the possible candidates and further promote a broader 
mechanistic approach to treating familial AF. 
 
HMR-1556 sensitivity of other familial AF-associated KCNQ1 mutations 
The physiologic constitutive activity S140G- IKs is caused by ultraslowed 
deactivation of the channel, hypothesized to be due to the salt bridge disruption 
between the V141/S140-R231-E160 residues in the closed state or stabilization 
between residues V141/S140-R237-E160 in the open state.17 The disruption or 
stabilization of the salt bridge and the S140G mutation itself may independently 
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or together confer increased sensitivity through an additional high affinity state. If 
the salt bridge perturbation is critical for enhanced sensitivity, then other gain-of-
function FAF-linked mutations in KCNQ1, R231C and R231H, may be similarly 
selectively inhibited. A concentration-response curve could be completed in a 
heterologous system to determine whether these mutations have similar 
enhanced sensitive to HMR-1556. Other potassium channel gain-of-function 
familial AF mutations include KCNQ1-IAP54-56 NPPA-S64R, and KCNEs: 
KCNE2-R27C, KCNE2-X124N, and KCNE3-V17M. Although the mechanism for 
IKs enhancement is not as well articulated with these mutations, whether they 
have increased sensitivity to HMR-1556 would be intriguing.  
 
Anticipated results: We predicted that mutations in R231 with slowed deactivation 
may have similar enhanced sensitivity to HMR-1556. Given that we do not know 
the effects of HMR-1556 on KCNQ1-KCNE2 or KCNQ1-KCNE3 channel 
complex, it is more difficult to anticipate the sensitivity of these mutations. 
However, because KCNE3-V17M does not increase KCNQ1 current (instead, 
increases HERG), it is less likely to have enhanced sensitivity to HMR-1556. The 
gain-of-function IKs AF-associated mutations may have enhanced sensitivity.  
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